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Vitiligo is an acquired chronic idiopathic disease manifesting mainly as white 
macules on the skin due to the destruction of melanocytes (Ezzedine et al, 
2015a). It is the most common depigmenting disorder affecting 0.5–2% of the 
population worldwide (Bergqvist & Ezzedine, 2020). Both sexes are equally 
affected, and there are no differences in rates of occurrence according to photo-
type or race (Boniface et al, 2018b). Although the depigmentation of the skin 
and hairs rarely causes any physical symptoms, vitiligo is not merely a cosmetic 
disease. Vitiligo may cause psychosocial problems and impair the quality of life 
(Ezzedine et al, 2015b; Silverberg & Silverberg, 2013). Therapeutic options for 
vitiligo are limited and the results are often unsatisfactory. This is partially 
caused by uncertainty in the etiopathogenetic mechanisms (Bergqvist & Ezze-
dine, 2020; Taieb et al, 2013). Multiple mechanisms have been considered to 
contribute to the destruction of melanocytes. These include autoimmune mecha-
nisms together with genetic and environmental factors as well as metabolic, 
oxidative stress and cellular abnormalities. However, the biological mediators 
and the molecular mechanisms that lead to metabolic defects, melanocyte dege-
neration and autoimmunity remain not fully understood (Bergqvist & Ezzedine, 
2020; Boniface et al, 2018b; Ezzedine et al, 2015a). MicroRNAs (miRNA), the 
regulators of gene expression, have been the objects of research since the early 
1990s (Gebert & MacRae, 2019; Jonas & Izaurralde, 2015). To date, much 
uncertainty still exists about the role of miRNAs in the pathogenesis of vitiligo 
(Yan et al, 2020). 
Psoriasis is a common inflammatory skin disease with a complex patho-
genesis (Boehncke & Schon, 2015). The prevalence of psoriasis in adults is 
0.91–8.5% depending on the ethnicity and geography, being higher at higher 
latitudes, and in Caucasians compared to other ethnic groups (Parisi et al, 
2013). However, psoriasis is equally prevalent in both sexes. Most commonly, 
psoriasis manifests as red scaly patches on the skin, but nails and joints can be 
affected as well (Boehncke & Schon, 2015). Moreover, multiple associated 
comorbidities have been described, with cardiometabolic diseases being the 
most prevalent ones (Takeshita et al, 2017). Pathogenetically, psoriasis is cha-
racterized by inflammation as well as abnormal proliferation and differentiation 
of keratinocytes. Within inflammation, the tumour necrosis factor (TNF) and 
the interleukin (IL)-23/T helper (Th) cell 17 axis play a central role (Boehncke 
& Schon, 2015; Harden et al, 2015b; Ogawa et al, 2018). Knowledge about the 
pathogenesis has enabled the development of several effective conventional and 
biological therapeutic agents (Amatore et al, 2019). However, every therapeutic 
agent is not equally effective for all psoriasis patients and the markers pre-
dicting individual responses before treatment still need to be identified (da Rosa 
et al, 2017; Hoffmann et al, 2011). Non-invasive diagnostic methods for skin 
diseases are being developed (Falcone et al, 2017; Orro et al, 2014), but the 
accurate diagnostic and prognostic markers for predicting the course of 
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psoriasis have not been developed yet. Therefore, extensive research on the 
pathogenetic mechanisms of psoriasis is still in progress (Boehncke & Schon, 
2015; Christophers et al, 2014; Fanoni et al, 2019; Liang et al, 2017; Sweeney 
et al, 2011). 
This study attempts to unravel the molecular mechanisms of vitiligo and 
psoriasis, focusing on local and systemic inflammation, the involvement of 
innate immunity and miRNAs in disease pathogenesis. 
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4. REVIEW OF THE LITERATURE 
4.1. Overview of vitiligo 
4.1.1. Clinical manifestation of vitiligo 
Clinically, depigmented macules on the skin and mucosa as well as depig-
mented hairs are characteristic to vitiligo (Ezzedine et al, 2015a). The first 
symptoms usually occur in young people; specifically, in 50% of cases vitiligo 
appears at an age younger than 20 (Ezzedine et al, 2015a) and in 25% of cases 
below the age of 10 (Boniface et al, 2018b). Based on the clinical picture, there 
are two types of vitiligo – non-segmental and segmental vitiligo (Ezzedine et al, 
2012). In the case of the most common form, non-segmental vitiligo, white 
macules affect multiple parts of the body in a symmetrical pattern, usually 
starting from the fingers, hands and face (Boniface et al, 2018b; Ezzedine et al, 
2012) (Figure 1). Segmental vitiligo lesions locate unilaterally in a segmental 
pattern and are commonly accompanied by depigmented hairs. This form of 
vitiligo progresses rapidly and is less responsive to the treatment than non-seg-





Figure 1. Non-segmental vitiligo (photographs taken by the author) 
 
The onset of non-segmental vitiligo is usually insidious but severe sunburn, 
pregnancy, skin trauma or emotional stress may precede the occurrence (Alik-
han et al, 2011). Generally, the course is slowly progressive (Ezzedine et al, 
2012). A progressive disease, also defined as an active disease, is marked by the 
development of new lesions and the extension of the old lesions (Ezzedine et al, 
2012). This is characterised by hypomelanotic lesions with poorly defined 
borders (Benzekri & Gauthier, 2017), numerous 1- to 5-mm depigmented 
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lesions as well as the Koebner phenomenon, the appearance of lesions on the 
lines of trauma. Inflammatory lesions are less common (Aboul-Fettouh et al, 
2017).  
Although there are rarely any physical symptoms other than depigmented 
macules on the skin, vitiligo patients, especially dark-skinned patients, have an 
impaired quality of life (Ezzedine et al, 2015b; Karelson et al, 2013; Silverberg 
& Silverberg, 2013). Moreover, the prevalence of depression as well as anxiety 
is higher in vitiligo patients in comparison to the general population (Lai et al, 
2017; Osinubi et al, 2018). 
In addition to psychological problems, patients with vitiligo exhibit an 
elevated frequency of autoimmune diseases, including the autoimmune thyroid 
disease, type 1 diabetes, Addison’s disease, pernicious anaemia, alopecia 
areata, systemic lupus erythematosus, systemic sclerosis, Sjögren’s syndrome 
and rheumatoid arthritis (Alikhan et al, 2011; Choi et al, 2017). Thyroid 
diseases are the most common, affecting 14.3% of patients with vitiligo. 
Furthermore, 20.8% of vitiligo patients have thyroid-specific autoantibodies 
(Vrijman et al, 2012). However, vitiligo can be a part of all types of auto-
immune polyendocrine syndromes that are present with a combination of  
Addison’s disease, hypoparathyroidism, ectodermal dysplasia, mucocutaneous 
candidiasis, alopecia areata, gonadal failure and/or pernicious anaemia (Alik-
han et al, 2011). Besides, vitiligo can be associated with ophthalmological and 
auditory problems (Alikhan et al, 2011). Specifically, up to 20% of vitiligo 
patients are affected by hearing impairment which may be caused by functional 
disorders in the intermediate cells (melanocytes) of the stria vascularis 
(Alikhan et al, 2011; Hong et al, 2009). Ocular anomalies, including choroidal 
abnormalities, uveitis, iritis or retinal findings, are caused by pigment distur-
bances and occur in up to 40% of patients (Alikhan et al, 2011; Karadag et al, 
2016). 
Frequent comorbidities for vitiligo are also chronic inflammatory skin dis-
orders such as psoriasis and atopic dermatitis (Alikhan et al, 2011; Mohan & 
Silverberg, 2015). Overall, 11.7% patients with vitiligo have a history of atopic 
dermatitis (Mohan & Silverberg, 2015). The prevalence of psoriasis among 
vitiligo patients varies from 4.0% (Powell & Dicken, 1983) to 7.6% (Sheth et 
al, 2013). A recent meta-analysis reported that compared to controls, vitiligo 
patients are 3.43-fold more likely to be diagnosed with psoriasis. Explanations 
for this association remain speculative (Yen & Chi, 2019). 
 
 
4.1.2. Etiopathogenesis of vitiligo 
According to histopathological and immunohistochemical studies, melanocytes 
and consequently melanin are absent in the lesional skin of vitiligo (Ezzedine et 
al, 2015a). However, sometimes occasional melanocytes can persist (Kim et al, 
2008). Multiple mechanisms are supposed to be involved in melanocyte 
destruction, including a genetic predisposition, environmental triggers, meta-
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bolic abnormalities, an impaired renewal of melanocytes, and altered inflam-
matory and immune responses (Boniface et al, 2018b). 
Epidemiological studies have shown that vitiligo tends to aggregate in 
families. Around 20% of vitiligo patients have at least one first-degree relative 
with vitiligo (Nath et al, 1994), and the risk ratio for first-degree relatives is 
increased up to 18-fold (Alkhateeb et al, 2003). A twin study in Caucasians 
found that the concordance of vitiligo was 23% in monozygotic twins (Alkha-
teeb et al, 2003). Genetic susceptibility to vitiligo is determined by several loci. 
Genome-wide association studies have identified many vitiligo-associated 
genes. Most of them encode immunoregulatory components (HLAI, HLAII, 
IFIH1, IL2RA, PTPN22, CTLA4), proteins involved in melanocyte function 
(TYR, OCA2, MC1R) and apoptotic regulators (CASP7, SERPINB9, BCL2L11, 
BAD) (Jin et al, 2016; Jin et al, 2012; Jin et al, 2010). 
As elevated levels of reactive oxygen species have been observed in vitiligo 
lesional skin and in melanocytes isolated from the skin of vitiligo patients (Li et 
al, 2017), it is believed that in genetically susceptible individuals, environ-
mental factors such as ultraviolet (UV) radiation, chemical agents or mechanical 
trauma may lead to an uncontrolled production of reactive oxygen species and 
oxidative stress (Boniface et al, 2018b). The stressed melanocytes (Rezk et al, 
2017) and surrounding keratinocytes (Richmond et al, 2017) can release 
proinflammatory cytokines and chemokines, such as the C-C motif chemokine 
ligand (CCL) 5, C-X-C motif chemokine ligand (CXCL) 8, CXCL9, CXCL10, 
CXCL12, CXCL16, which are important for the recruitment of immune cells 
(Bastonini et al, 2019; Rezk et al, 2017; Richmond et al, 2017). Moreover, nuc-
leic acids that can be released from damaged melanocytes and/or keratinocytes 
can be recognised by different pattern recognition receptors (PRR) leading to 
the activation of innate immunity and an inflammatory response that in turn 
activates adaptive immunity (Boniface et al, 2018b; Wang et al, 2015a). Indeed, 
melanocyte-specific antibodies, which are uncommon in healthy persons, have 
been found to circulate in the blood and are deposited in the skin of vitiligo 
patients (Sandoval-Cruz et al, 2011). Additionally, skin-homing melanocyte-
specific cytotoxic T lymphocytes have been found circulating in the blood of 
vitiligo patients (Boniface et al, 2018a; Cheuk et al, 2017; Richmond et al, 
2018; van den Boorn et al, 2009). 
Although vitiligo is clinically not an inflammatory disease, skin deposits of 
inflammatory cells and an increased expression of inflammatory cytokines are 
characteristic, especially to the marginal zone of a vitiligo lesion, also known as 
perilesional skin (Sandoval-Cruz et al, 2011). Perilesional skin and to a lesser 
extent lesional skin is infiltrated by T lymphocytes, B lymphocytes, Langerhans 
cells, dendritic cells (DCs) and histiocytes (Montes et al, 2003; Sandoval-Cruz 
et al, 2011; Wang et al, 2011). The population of T cells consists of both, CD8+ 
and CD4+ T cells, with an increased CD8+/CD4+ ratio. It has previously been 
observed that these cells are polarised towards a type-1-like subset, producing 
the TNF and interferon (IFN)-γ (Wankowicz-Kalinska et al, 2003). Van den 
Boorn et al. showed that CD8+ T cells isolated from perilesional skin are 
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cytotoxic against melanocytes (van den Boorn et al, 2009). Previous results 
demonstrate an increased expression of several cytokines (TNF, IFN-γ, IL-1b, 
IL-6, IL-10, IL-17, IL-22, IL-23A, transforming growth factor [TGF]-β, CCL5, 
CXCL10, CXCL12) and their receptors (IL10RA, IL10RB, IL20RB, IL22RA2, 
IL28RA, IFNA1, IFNB1) in the skin, peripheral blood mononuclear cells 
(PBMC) and/or the serum of vitiligo patients (Bhardwaj et al, 2017; Grimes et 
al, 2004; Mansuri et al, 2016; Moretti et al, 2002; Regazzetti et al, 2015; 
Reimann et al, 2012; Rezk et al, 2017; Rätsep et al, 2008; Singh et al, 2016). 
Melanocytes and infiltrating cells are not the only cell populations that are 
altered in vitiligo pathogenesis (Bastonini et al, 2019). Keratinocytes in the de-
pigmented epidermis are more vulnerable to apoptosis and produce smaller 
amounts of melanogenic mediators than in normal skin. Furthermore, the 
expression of genes involved in keratinocytes’ differentiation and cornification 
is dysregulated in the vitiligo lesional epidermis (Moretti et al, 2009; Singh et 
al, 2017). In addition, fibroblasts show a senescent phenotype in the skin of 
patients with vitiligo (Bastonini et al, 2019). 
However, the exact mechanisms underlying vitiligo still remain unknown 
and the initial events that breach the self-tolerance to melanocyte-specific anti-
gens and the factors that cause the destruction of melanocytes still remain 
unidentified. 
 
4.1.3. Management of vitiligo 
The diagnosis of vitiligo is usually made based on the clinical picture (Ezzedine 
et al, 2015a). The Wood’s lamp, a handheld UVA emitting device, facilitates 
determining the extent and activity of vitiligo, as well as monitoring the 
response to therapy (Alghamdi et al, 2012). However, sometimes distinguishing 
between vitiligo and other diseases manifesting as depigmented or hypopig-
mented patches can be difficult. Common disorders that can have a similar pre-
sentation to vitiligo include nevus depigmentosus, idiopathic guttate hypomela-
nosis, pityriasis versicolor and chemically-induced leukoderma. In diagnostic 
difficulties a biopsy can be required (Alikhan et al, 2011). 
For the treatment of vitiligo, immunosuppressive and pigmentation stimu-
lating measures can be used. These include topical corticosteroids, topical 
calcineurin inhibitors, phototherapy, oral steroids and grafting procedures 
(Taieb et al, 2013). Recently, afamelanotide (Lim et al, 2015), Janus kinase 
inhibitors (Liu et al, 2017; Rothstein et al, 2017), simvastatin (Vanderweil et al, 
2017), apremilast (phosphodiesterase 4 inhibitor) (Majid et al, 2019) and IL-15 
signalling blockade (Richmond et al, 2018) have shown promising treatment 
results but further studies are required to clarify the efficacy and safety of these 
measures (Abdel-Malek et al, 2020; Frisoli et al, 2020). The therapeutic options 
for vitiligo depend on the extent, the distribution and the activity of the disease 
as well as on the patient’s age, phototype and intention to treat the disease 
(Bergqvist & Ezzedine, 2020). Unfortunately, the care often extends over a long 
period of time and patients are frequently frustrated by the failure of treatments. 
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Therefore, camouflage techniques, depigmenting agents and psychological 
interventions are important parts of the global management of vitiligo (Rodri-
gues et al, 2017; Taieb et al, 2013).  
There have been attempts to find biomarkers that allow for an early accurate 
diagnosis, prognosis, and for the prediction of treatment response of vitiligo 
(Speeckaert et al, 2017). Histopathology is considered the gold standard in the 
assessment of disease activity. The presence of an inflammatory infiltrate with 
the gradual loss of melanocytes in perilesional biopsies is the most straight-
forward sign of the disease activity in vitiligo (Yadav et al, 2016), but skin 
biopsies are too invasive for biomarker purposes (Speeckaert et al, 2017). The 
most evidence for circulating biomarkers is currently available for cytokines IL-
1β, IL-17, IFN-γ and TGF-β (Bhardwaj et al, 2017; Singh et al, 2016), chemo-
kines CXCL10 and CXCL9 (Rashighi et al, 2014; Wang et al, 2016c), the 
soluble cell surface marker CD25 (Speeckaert et al, 2016), autoantibodies 
(Harning et al, 1991) and oxidative stress markers (Mitra et al, 2017). However, 
further studies are necessary to find novel biomarkers, to validate the use of 
biomarkers for clinical trials and daily practice. 
 
 
4.2. Overview of psoriasis 
4.2.1 Clinical manifestation of psoriasis 
The most common form of psoriasis is plaque psoriasis. It manifests itself as 
monomorphic, sharply demarcated erythematous plaques covered by silvery 
scales (Figure 2). There can be a few plaques, which can extend over larger 
areas, and they can also occur as erythroderma affecting the entire body’s sur-
face (Boehncke & Schon, 2015). Based on the extent of the disease, the activity 
of the erythema, the intensity of the infiltration and scaling of psoriatic plaques, 
the psoriasis area and severity index (PASI) is calculated (Schmitt & Wozel, 
2005). Although there is no international consensus on the categorisation of the 
severity of psoriasis (Strober et al, 2020), psoriasis with PASI > 10 (Finlay, 
2005; Mrowietz et al, 2011) or > 12 (Schmitt & Wozel, 2005) can be classified 
as moderate to severe or severe. It is now well established that patients with an 
early onset of the disease (< 40 years) have a more severe course, whereas 
patients with a late onset (≥ 40 years) tend to have a milder form of the disease 





Figure 2. Plaque psoriasis (photographs taken by the author) 
 
Although psoriasis affects the skin, it is not merely a skin-restricted disease but 
a systemic inflammatory disorder, especially in the case of severe psoriasis 
(Boehncke & Schon, 2015; Dowlatshahi et al, 2013; Reich, 2012). Among 
patients with psoriasis, 50% have concomitantly nail involvement and 30% 
have psoriatic arthritis. Furthermore, many co-morbidities are associated with 
psoriasis, e.g., obesity, diabetes, cardiovascular diseases, non-alcoholic fatty 
liver disease, Crohn’s disease, lymphoma, cancer, anxiety and depression, many 
of which can be the result of a persistent inflammation in the body in the case of 
severe psoriasis (Boehncke & Schon, 2015; Reich, 2012). 
 
 
4.2.2. Etiopathogenesis of psoriasis 
Based on the clinical picture and histopathological findings, inflammation and 
the abnormal proliferation of keratinocytes are the hallmark features of psoriasis 
(Boehncke & Schon, 2015). Histopathologically, the epidermis is markedly 
thickened and in the dermis blood vessels are dilated. The inflammatory in-
filtrate in the skin mostly consists of T lymphocytes, DCs and neutrophils 
(Lowes et al, 2014). A genetic predisposition and environmental factors are 
important in the disease pathogenesis (Harden et al, 2015b). 
The importance of genetic factors is supported by twin and family studies as 
well as genome-wide studies. The concordance rate for monozygotic twins is 
approximately 70% and for dizygotic twins it is about 20% (Harden et al, 
2015b). Genome-wide scans for psoriasis-associated genes have identified 
genes that mostly regulate antigen presentation (HLA-Cw6, ERAP1, ERAP2, 
MICA), the IL-23 axis (IL12B, IL23A, IL23R, JAK2, TYK2), T cell development 
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and polarisation (RUNX3, STAT3, TAGAP, IL4, IL13), innate immunity 
(CARD14, REL, TRAF3IP2, DDX58, IFIH1) and the negative regulators of 
immune responses (TNIP1, TNFAIP3, NFKBIA, ZC3H12C, SOCS1) (Elling-
haus et al, 2012; Ellinghaus et al, 2010; Tsoi et al, 2012; Tsoi et al, 2017). 
From the immunopathogenetic mechanisms, the TNF-α pathway and IL-
23/Th17 pathway have a central role in the development of psoriasis (Ogawa et 
al, 2018). It is proven that complexes of host deoxyribonucleic acid (DNA) and 
the epidermis-produced antimicrobial peptide cathelicidin LL-37 stimulate 
dermal plasmacytoid DCs. Activated DCs produce proinflammatory mediators 
such as IFN-α, TNF-α and IL-23. TNF-α is additionally released by a broad 
range of other cell types including macrophages, lymphocytes, keratinocytes 
and endothelial cells and it exerts its activities on several cell types. IL-23 
drives the differentiation of Th17 cells that produce several mediators such as 
IL-17A, IL-17F and IL-22, which in turn induce inflammation and keratinocyte 
proliferation (Bettelli et al, 2007; Lowes et al, 2014). From these cytokines, IL-
17A, the most abundant in psoriatic skin, is additionally produced by other skin 
infiltrating cells such as the CD8+ T cells, γδT cells, neutrophils and mast cells 
(Cai et al, 2013; Hijnen et al, 2013; Kim et al, 2016; Laggner et al, 2011; Lin et 
al, 2011). Furthermore, antimicrobial peptides, cytokines and chemokines 
secreted by keratinocytes act as chemoattractants for the infiltrating immune 
cells (Buchau & Gallo, 2007). Thus, in the case of psoriasis a positive feedback 
loop exists between the cells of the immune system and the resident epithelial 
cells. Changes are most prominent in the lesional skin of psoriasis, but there are 
also clear signs of inflammation and immune cell infiltration in the seemingly 
healthy skin of the patients (Chiricozzi et al, 2015; Gudjonsson et al, 2010; 
Keermann et al, 2015). 
There is a growing body of evidence about the importance of innate im-
munity in psoriasis pathogenesis (Christophers et al, 2014; Liang et al, 2017; 
Sweeney et al, 2011). Although knowledge about TNF-α, IL-23 and IL-17 as 
the key cytokines in the pathogenesis of psoriasis has enabled the development 
of novel effective drugs that block the associated pathways (Liang et al, 2017; 
Ogawa et al, 2018), it is still debated whether psoriasis is autoimmune, i.e., 
caused by autoantigen-specific T cells, or rather autoinflammatory due to the 
excessive stimulation of innate immune receptors and inflammasomes. 
 
 
4.2.3. Management of psoriasis 
A diagnosis of plaque psoriasis can be made by physical examination in the vast 
majority of patients. A skin biopsy can be helpful for challenging cases 
(Boehncke & Schon, 2015). Disorders that may be mistaken for plaque 
psoriasis include parapsoriasis, pityriasis rubra pilaris, seborrheic dermatitis, 
lichen simplex chronicus, atopic dermatitis, nummular eczema, lichen planus, 
tinea corporis and subacute cutaneous lupus erythematosus (Bordignon et al, 
2011; Lebwohl, 2003; Napolitano et al, 2016). 
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Psoriasis has no known cure but many therapies can reduce or nearly stop 
symptoms (Amatore et al, 2019). Topical therapy is the primary mode of 
treatment for plaque psoriasis in patients with limited skin involvement (Menter 
et al, 2009) but is often insufficient for patients with moderate to severe 
psoriasis (Menter et al, 2020; Menter et al, 2019). The most commonly used 
topical agents for plaque psoriasis are corticosteroids, vitamin D analogues, 
calcineurin inhibitors, salicylic acid, anthralin and emollients (Menter et al, 
2009). The major treatment options for moderate to severe psoriasis include 
phototherapy and systemic medications (Amatore et al, 2019; Elmets et al, 
2019). There are two types of systemic therapeutic options: non-biological and 
biological agents (Amatore et al, 2019). Among non-biological medications, 
methotrexate, cyclosporine and apremilast work by targeting the immune 
system, whereas acitretin works predominantly by decreasing keratinocyte 
hyperproliferation and restoring the normal epidermal differentiation (Menter et 
al, 2020). In the past decade, several biologics have been developed and 
approved for the treatment of psoriasis (Amatore et al, 2019). With some excep-
tions, biologics are monoclonal antibodies. The biological agents currently in 
use include TNF-α, IL-17A, IL-23, or IL-12/IL-23 inhibitors (Menter et al, 
2019). A treatment to which all patients respond adequately is not available yet 
(Kaushik & Lebwohl, 2019a; b). 
The prediction of treatment response and overall prognosis of psoriasis has 
remained a challenge (Amatore et al, 2019; Kaushik & Lebwohl, 2019a; b). 
Moreover, making accurate diagnosis and differentiating psoriasis from other 
chronic inflammatory skin diseases can be difficult (Boehncke & Schon, 2015). 
Therefore, multiple biomarker candidates have been identified at the genome, 
transcriptome, proteome and metabolome level (Jiang et al, 2015). Some of the 
numerous potential biomarkers include HLA-Cw6 (Gudjónsson et al, 2002), 
CCL27 (Gudjonsson et al, 2010), C10orf99 (Gudjonsson et al, 2009; Keermann 
et al, 2015), NOS2 (Quaranta et al, 2014), S100A7 and S100A7 (Gudjonsson et 
al, 2009; Williamson et al, 2013), IL36G and IL-36γ (D'Erme et al, 2015; 
Keermann et al, 2015), miR-143, miR-223 (Løvendorf et al, 2014), glutamate, 
phenylalanine, urea and spermidine (Kang et al, 2017; Pohla et al, 2020). As no 
single marker has shown to be robustly specific to psoriasis, combining several 
potential biomarkers into a single multicomponent biomarker results in a more 
accurate diagnostic tool. However, molecular diagnostic methods have not been 




Inflammasomes are multimolecular complexes that assemble in the cytosol of 
cells in response to exogeneous as well as endogeneous danger signals, and 
protelytically generate active forms of the inflammatory cytokines IL-1β and 
IL-18 (Guo et al, 2015). Inflammasomes are made up of three components: 
sensors binding with different exogenous and endogenous danger signals; 
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proteolytic enzymes called caspases; and the adaptor protein PYD and CARD 
domain containing (PYCARD, also known as ASC) that enables the sensors to 
bridge effector caspases, of which caspase 1 is the most common (Rathinam & 




Figure 3. The activation of the inflammasome. The formation of the inflammasome and 
the synthesis of pro-IL-1β is induced by various pathogen-associated molecular patterns 
(PAMPs) and damage-associated molecular patterns (DAMPs) that are recognized by 
sensors. The subsequent production of biologically active IL-1β is mediated by inflam-
masomes. NLRP1, nucleotide-binding domain leucine-rich repeat-containing (NLR) 
family, pyrin domain (PYD)-containing; AIM2, absent in melanoma 2; PYCARD, PYD 
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The most well-established inflammasomes, named by their receptors, are 
NLRP1 (nucleotide-binding domain leucine-rich repeat-containing [NLR] fami-
ly, pyrin domain [PYD]-containing 1), NLRP3 (NLR family, PYD-containing 
3), NLRC4 (NLR family, caspase activation and recruitment domain [CARD]-
containing 4), AIM2 (absent in melanoma 2) and pyrin (Rathinam & Fitzgerald, 
2016). The classic outcome of inflammasome activation is inflammation 
through the cleavage of proinflammatory IL-1 family cytokines into their bio-
active forms, IL-1β and IL-18, and pyroptosis, which is a type of inflammatory 
cell death (Guo et al, 2015). However, many alternative functions have been 
associated with inflammasomes. Therefore, in addition to inflammation, inflam-
masomes can regulate many other cellular processes, including cell prolifera-
tion, gene transcription and tumourigenesis (Rathinam & Fitzgerald, 2016). 
The conditions that are characterised by an aberrant innate immune response 
to endogenous signals due to the dysregulation of inflammasomes are called 
autoinflammatory disorders (Havnaer & Han, 2019). There are several mono-
genic and multifactorial autoinflammatory syndromes that along with other 
symptoms manifest in dermatological signs. Well-known examples are the 
PAPA syndrome, including pyogenic arthritis, pyoderma gangrenosum and 
acne, and the PASH syndrome, consisting of pyoderma gangrenosum, acne and 
hidradenitis suppurativa (Havnaer & Han, 2019). However, alterations in 
inflammasomes have been observed in the pathogenesis of several diseases that 
are not classical autoinflammatory diseases, including diabetes, Alzheimer’s 
disease, atherosclerosis and cancer (Rathinam & Fitzgerald, 2016). 
There is much uncertainty about the relationship between the pathogenesis 
of vitiligo and inflammasomes. In patients with vitiligo, polymorphisms of 
NLRP1 have been demonstrated (Jin et al, 2007). The expression of IL1B 
mRNA as well as the protein levels of NLRP1 and IL-1β have been found to be 
increased in the perilesional skin of active vitiligo (Marie et al, 2014; Wang et 
al, 2011). Although in normal skin NLRP1 is known to be expressed in 
Langerhans cells, in vitiligo perilesional skin NLRP1 is additionally expressed 
in melanocytes and keratinocytes (Kummer et al, 2007).  
In comparison to vitiligo, more is known about the associations between 
inflammasomes and psoriasis. Polymorphisms of NLRP1, NLRP3 and CARD8 
have been linked to an increased susceptibility to psoriasis (Carlström et al, 
2012; Ekman et al, 2014). The upregulation of AIM2 (Dombrowski et al, 2011), 
CASP1, CASP5, CASP4 and PYCARD (Johansen et al, 2007; Salskov-Iversen et 
al, 2011) has been identified in psoriatic lesional skin. Furthermore, CARD14, 
which encodes the caspase recruitment domain-containing protein 14, has been 
identified as the gene responsible for the association of the psoriasis suscepti-
bility locus 2 (PSORS2) with psoriasis, and mutations in CARD14 have been 
reported in patients with psoriasis (Jordan et al, 2012). Mutations in CARD14 
are associated with an increased nuclear-factor kappa B (NF-κB) activation and 
an upregulation of psoriasis-associated genes in keratinocytes leading to clinical 
manifestations of the disease (Liang et al, 2017). However, it is still unclear 
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whether innate or adaptive immunological mechanisms dominate in the patho-




Autophagy is the enzymatic digestion of cytoplasmic contents to maintain cel-
lular homeostasis. In this process, cytoplasmic components are trapped within 
vesicles called autophagosomes, which fuse with lysosomes and lead to the 
proteolytic degradation of the trapped components (Figure 4). Depending on the 
cellular organelles that are being degraded, specialised forms of autophagy have 
been described, including mitophagy (degradation of mitochondria), nucleo-
phagy (degradation of nuclei), and ER-phagy (degradation of the endoplasmic 
reticulum). Autophagy is controlled by macromolecular signalling complexes, 
among which beclin 1 with the UV radiation resistance-associated gene protein 
(UVRAG), WD repeat domain, phosphoinositide interacting 1 (WIPI1) and 
microtubule-associated protein light chain 3 (LC3) are positive regulators, and 
the mammalian target of rapamycin (mTOR) is a negative regulator (Mizushima 
et al, 2010; Yu et al, 2015). In addition, WIPI1 and LC3 are also some of the 
key components of an autophagosome (Mizushima et al, 2010). Although 
autophagy is primarily a mechanism for degrading damaged cellular organelles 
and proteins to maintain cellular homeostasis, it is shown that the dysregulation 
of autophagy can be involved in pathological processes including auto-
immunity, infections and malignant tumours (Yu et al, 2015; Zhou & Zhang, 
2012). Moreover, autophagy plays a critical role in normal epidermal develop-
ment, and an impaired autophagy may contribute to the pathogenesis of diseases 
with a disturbed epidermal differentiation, such as psoriasis (Akinduro et al, 
2016). 
The idea that the dysfunction of autophagy can be involved in vitiligo patho-
genesis is supported by Jeong et al. who demonstrated that variation in the 
UVRAG gene contributes to the risk of non-segmental vitiligo in the Korean 
population (Jeong et al, 2010), and by Wang et al. who found that several genes 
involved in the autophagy process were dysregulated in the leukocytes of 
generalised vitiligo patients (Wang et al, 2016b). Furthermore, autophagy 
deficiency leads to premature senescence and a decreased proliferation of 
melanocytes (Zhang et al, 2015). Melanosomal autophagy in stressed melano-
cytes mediates antigen presentation and DC maturation (Xie et al, 2016). 
Actually, melanosomes are also lysosome-related organelles whose maturation 
is controlled by molecules overlapping with autophagy regulators like WIPI1 
and LC3 (Ho et al, 2011; Yun et al, 2016). However, little is currently known 





Figure 4. The process of autophagy. The autophagy inducing signal causes the forma-
tion of a sequestering membrane called phagophore. The microtubule-associated protein 
light chain 3 (LC3) conjugates with the sequestering membrane and controls the elonga-
tion of phagophore. As the phagophore expands, cytoplasmic constituents, including 
organelles, such as mitochondria and endoplasmic reticulum, are enfolded, and it results 
in the formation of an autophagosome. These vesicles fuse with lysosome, and the cyto-
plasmic proteins are proteolytically degraded. UVRAG, beclin 1 with the UV radiation 
resistance-associated gene protein; WIPI1, WD repeat domain, phosphoinositide inter-
acting 1; mTOR, mammalian target of rapamycin. 
 
 
4.5. Biological functions of miRNAs 
MiRNAs are small, approximately 22 nucleotide-long, non-coding RNAs that 
regulate gene expression. MiRNAs inhibit gene expression through translational 
repression or messenger RNA (mRNA) destabilisation. In order to suppress 
gene expression, in most cases, miRNAs bind with partial complementarity to 
sequences in the 3` untranslated region (3`UTR) of target mRNAs (Figure 5) 
(Bartel, 2004). As one miRNA can bind to hundreds of genes and multiple 
miRNAs can regulate the same gene simultaneously, the biological effect of 
miRNAs can be remarkable (Jonas & Izaurralde, 2015). It should be noted that 
























through suppressing inhibitory proteins or more directly through binding to the 
3’UTR and hindering the binding of proteins that otherwise would cause rapid 




Figure 5. The biogenesis and mechanism of the action of miRNAs. MiRNAs are 
synthesised in the nucleus by RNA polymerase II as part of longer transcripts. These 
long pri-miRNAs are cleaved by the ribonuclease III enzyme Drosha and RNA binding 
protein DiGeorge Syndrome Critical Region 8 (DGCR8) complex to hairpin-like pre-
miRNAs. Pre-miRNAs are exported to the cytoplasm, where they are further processed 
by the RNase III endonuclease Dicer to a short RNA duplex. One strand of the duplex is 
incorporated into the RNA-induced silencing complex (RISC). The second strand can 
be loaded into another RISC or it is degraded. MiRNA binds with the partial comple-
mentarity in the 3’ untranslated region (UTR) of the target messenger RNA (mRNA), 


















Destabilisation of the target
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The first miRNA lin-4 was described in 1993 in nematode Caenorhabditis 
elegans (Lee et al, 1993). Since then new miRNAs have been discovered at an 
extremely high speed, and 48,860 different miRNAs in different species have 
been described so far. The human genome has suggested to contain over 2,500 
miRNAs (Kozomara et al, 2019), and more than 60% of human protein-coding 
genes own predicted miRNA target sites indicating that miRNAs are essential 
for the normal functioning and development of all organisms (Gebert & 
MacRae, 2019). Accordingly, these small RNAs have been shown to regulate 
numerous cellular processes, including cell proliferation, differentiation, 
development, signal transduction, metabolism, homeostasis, apoptosis and 
immune responses (Gebert & MacRae, 2019; Jonas & Izaurralde, 2015; Rebane 
& Akdis, 2013). For instance, miR-155 targets the suppressor of the cytokine 
signalling SOCS1 and thereby activates IFN signalling in CD8+ cytotoxic T 
cells (Dudda et al, 2013). In the skin, through targeting CTLA4, which 
suppresses the inhibitory cytotoxic T lymphocyte associated protein, miR-155 
enhances T cell responses (Sonkoly et al, 2010). Based on this and several other 
studies, it can be concluded that, miRNA dysregulation can be associated with 
the pathogenesis of various diseases, including common dermatoses, such as 
psoriasis (Hermann et al, 2017; Sonkoly et al, 2007), atopic dermatitis (Rebane 
& Akdis, 2013; Rebane et al, 2014; Sonkoly et al, 2010; Vaher et al, 2019) and 
allergic contact dermatitis (Vennegaard et al, 2012). 
One of the interesting characteristics of miRNAs is that they are secreted and 
can be found in quantitative levels in all extracellular fluids, for example, 
serum, urine and tears (Gebert & MacRae, 2019). Accordingly, a growing 
number of reports have shown that subsets of extracellular miRNAs may have 
clinical relevance as biomarkers for a variety of diseases, including cancer, viral 
infections, nervous system disorders, cardiovascular disorders and skin 
disorders (Hanna et al, 2019; Hayes et al, 2014; Lv et al, 2014; O'Brien et al, 
2018; Wang et al, 2016a). These biomarkers can be potentially used to indicate 
the presence, the stage and the prognosis of the disease, as well as the therapy 
response (Condrat et al, 2020; Hanna et al, 2019). For the application of 
miRNAs as biomarkers, numerous ongoing clinical trials have been initiated 
(https://clinicaltrials.gov). 
In addition, due to their gene-regulation properties, miRNAs have become 
attractive targets for novel therapeutic approaches. MiRNA mimics and mole-
cules targeted at miRNAs, called antimiRs, have shown promise in preclinical 
development (Rupaimoole & Slack, 2017). Several miRNA therapeutics have 
reached clinical trials (Bajan & Hutvagner, 2020), including a mimic of miR-29 
for treating scleroderma (Gallant-Behm et al, 2019), and antimiRs targeted at 
miR-122 for treating chronic hepatitis C (Bajan & Hutvagner, 2020) and 
antimiR-155 for treating cutaneous T cell lymphoma (Seto et al, 2018). One of 
the biggest challenges in developing miRNA‐based therapeutics is to identify 
the best miRNA candidates or miRNA targets. Other challenges include safe, 
specific and efficient in vivo delivery methods and enhancing the stability of 
RNA-based therapeutic agents. Therefore, miRNA-based therapeutics have not 
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been developed and used as widely as antibody-based therapeutics. Even so, in 
future, miRNA overexpression and suppression may be applied clinically in 
addition to other biological therapeutics (Rupaimoole & Slack, 2017). 
 
 
4.6. MiRNAs in psoriasis and vitiligo 
In psoriatic patients, miRNA expression has been extensively studied and so far 
the dysregulation of more than 250 miRNAs either in the skin or blood cells has 
been determined (Hawkes et al, 2016). Moreover, the functions of multiple 
miRNAs have been associated with psoriasis, including miR-21 (Meisgen et al, 
2012), miR-31 (Peng et al, 2012), miR-99a (Lerman et al, 2011), miR-125b (Xu 
et al, 2011), miR-135b (Joyce et al, 2011), miR-138 (Fu et al, 2015), miR-146a 
(Srivastava et al, 2017), miR-155 (Wang et al, 2020), miR-203 (Sonkoly et al, 
2007), miR-210 (Zhao et al, 2014), miR-221, miR-222 (Zibert et al, 2010) and 
miR-424 (Ichihara et al, 2011). Among these, miR-146a is one of the most 
highly upregulated miRNAs in psoriatic skin (Sonkoly et al, 2007). miR-146a is 
a well-known anti-inflammatory miRNA that inhibits the NF-κB pathway by 
targeting TRAF6 and IRAK1 (Taganov et al, 2006). In addition to its anti-
inflammatory role, miR-146a also suppresses the proliferation of keratinocytes 
(Hermann et al, 2017). Other psoriasis-associated miRNAs also regulate the 
proliferation and differentiation of keratinocytes, including miR-31 (Peng et al, 
2012), miR-99a (Lerman et al, 2011), miR-125b (Xu et al, 2011), miR-135b 
(Joyce et al, 2011), miR-203 (Sonkoly et al, 2007), miR-221, miR-222 (Zibert 
et al, 2010) and miR-424 (Ichihara et al, 2011). Inflammation in psoriasis is 
believed to be regulated in addition to miR-146a (Hermann et al, 2017; 
Taganov et al, 2006) by miR-21 (Meisgen et al, 2012), miR-138 (Fu et al, 
2015), miR-155 (Wang et al, 2020) and miR-210 (Zhao et al, 2014). However, 
studies on miRNAs to find potential diagnostic biomarkers and treatment 
targets for psoriasis are still ongoing (Hawkes et al, 2016). 
In patients with vitiligo, the aberrant expression of 66 miRNAs in the skin 
(Mansuri et al, 2014; Vaish et al, 2019), 69 miRNAs in the serum (Shi et al, 
2016; Shi et al, 2013) and 100 miRNAs in the whole blood (Shang & Li, 2017) 
has been demonstrated by the microarray analysis. From these miRNAs, miR-1, 
miR-184, miR-328, miR-383 and miR-577 are similarly dysregulated in the 
whole blood and skin of vitiligo patients (Mansuri et al, 2016). The dysregu-
lation of multiple miRNAs has been confirmed using the quantitative reverse 
transcription-polymerase chain reaction (qRT-PCR). Namely, the upregulation 
of miR-25 (Shi et al, 2016) and miR-9 (Su et al, 2019) as well as the down-
regulation of miR-211 (Sahoo et al, 2017) has been demonstrated in the skin of 
vitiligo patients. Also, the dysregulation of several miRNAs has been shown to 
appear in the serum (let-7b, miR-15b, miR-16, miR-25, miR-451) (Shi et al, 
2016), in the PBMCs (miR-224-3p, miR-4712-3p, miR-3940-5p, miR-155) (Lv 
et al, 2019; Wang et al, 2015b) and in the whole blood (miR-1238-3p, miR-202-
3p, miR-630 miR-766-3p) (Shang & Li, 2017) of vitiligo patients. For 
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aberrantly expressed miRNAs, several putative target genes have been identi-
fied (Mansuri et al, 2016; Sahoo et al, 2017; Vaish et al, 2019). Most of them 
are associated with autoimmune mechanisms (IL1B, IL2RG, PTPN22), melano-
cyte functioning (TYRP1, TYR, TRPM1, EDN1) or oxidative stress and cellular 
energy metabolism (HSP60, HSP70, G6PD, PPARGC1A) (Dwivedi et al, 2013; 
Mansuri et al, 2016; Sahoo et al, 2017; Shi et al, 2016; Vaish et al, 2019; Wang 
et al, 2016d). 
It has been shown that miR-25, the miRNA upregulated in the skin and 
serum of vitiligo patients, is induced by oxidative stress in melanocytes. miR-25 
suppresses the level of MITF, a transcription activator of melanogenesis-related 
genes, which leads to the dysfunction of melanocytes and facilitates the 
oxidative stress-induced apoptosis. Moreover, miR-25 suppresses the produc-
tion and secretion of growth factors in keratinocytes (Shi et al, 2016). Another 
upregulated miRNA in vitiligo skin, miR-9, has been found to inhibit adhesion 
and migration of melanocytes (Su et al, 2019). miR-211 is thought to regulate 
mitochondrial energy metabolism in melanocytes (Sahoo et al, 2017) and also 
melanocyte migration (Su et al, 2020).  
Single nucleotide polymorphisms in miRNA genes can affect the phenotypes 
or the development of diseases. As the computational analysis predicted that 
miR-196a-2 could putatively target the TYRP1 mRNA, whose protein is the key 
enzyme in the synthesis of melanin, miR-196a-2 was selected for genetic study 
in the Han Chinese population. The CC genotype of rs11614913 in miR-196a-2 
was found to decrease the susceptibility to vitiligo through regulating oxidative 
stress by targeting TYRP1 and TYR (Cui et al, 2015; Huang et al, 2013). How-
ever, although recent studies have emphasised the implication of miRNAs in 
vitiligo, there is still little information about the role of particular miRNAs in 
the pathogenesis of this disease (Yan et al, 2020). 
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5. SUMMARY OF THE LITERATURE REVIEW 
Vitiligo is a chronic skin disease that manifests as depigmented macules on the 
skin due to the destruction of melanocytes (Ezzedine et al, 2015a). As the onset 
of vitiligo is often during childhood or adolescence and the white macules 
mostly locate on visible body regions (Boniface et al, 2018b; Ezzedine et al, 
2015a), vitiligo affects the quality of life (Karelson et al, 2013; Lai et al, 2017; 
Osinubi et al, 2018; Silverberg & Silverberg, 2013). A lack of knowledge about 
the pathogenesis of vitiligo has impeded the development of effective methods 
of treatment (Boniface et al, 2018b; Ezzedine et al, 2015a; Taieb et al, 2013). 
Although vitiligo is generally considered to be an autoimmune disorder, the 
mechanisms that lead to the break-down of self-tolerance, the destruction of 
melanocytes and the maintenance of the disease progression still remain unclear 
(Boniface et al, 2018b). In addition, so far, little attention has been paid to the 
role of miRNAs in the pathogenesis of vitiligo (Yan et al, 2020). 
Psoriasis is a common chronic inflammatory disease that is characterized by 
erythematous and scaly plaques on the skin and often also by nail changes and 
psoriatic arthritis (Boehncke & Schon, 2015). Biological therapy has improved 
the results of the treatment but the therapeutic agents are not equally effective 
for all psoriasis patients. To date we are unable to predict the treatment outcome 
and the course of the disease (Amatore et al, 2019; da Rosa et al, 2017; Hoff-
mann et al, 2011). A cross-talk between the innate and the adaptive immune 
system in the pathogenesis of psoriasis has been a popular subject of research. 
However, it is still unknown whether psoriasis is rather autoimmune or 
autoinflammatory disease (Boehncke & Schon, 2015; Christophers et al, 2014; 
Liang et al, 2017; Sweeney et al, 2011). 
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6. AIMS OF THE STUDY 
The general purpose of this study was to acquire additional knowledge about 
the pathogenesis of the two chronic dermatoses – vitiligo and psoriasis – to 
uncover novel factors and pathways that could be associated with these diseases 
and used as possible diagnostic or prognostic markers or therapeutic targets in 
the future.  
 
The specific aims of the study were: 
1. to investigate the local and systemic inflammatory response in vitiligo and 
psoriasis; 
2. to get an insight into the immune cell infiltration in the lesional and non-
lesional skin of vitiligo and psoriasis patients; 
3. to test the involvement of inflammasomes and autophagy in the studied 
dermatoses; 
4. to study the expression changes and role of miRNAs in vitiligo pathogenesis. 
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7. SUBJECTS AND METHODS 
7.1. Ethical considerations 
Case-control studies were conducted at the Dermatology Clinic of Tartu Uni-
versity Hospital. The studies were approved by the Research Ethics Committee 
of the University of Tartu. The numbers of the approvals are as follows: 207/T-
12, 219/T-28, 236/M-26 and 244/M-14. All of the participants signed a written 
informed consent form. 
 
 
7.2. Characteristics of the study participants 
Individuals at the age of ≥ 18 years were invited to participate in the study. A 
total of 23 patients with non-segmental vitiligo (6 males and 17 females, ages 
ranging from 19–60 years); 43 patients with plaque psoriasis (33 males and 10 
females, ages ranging from 20–65 years) and 32 control individuals (8 males 
and 24 females, ages ranging from 22–57) were included (Table 1). All of the 
participants were unrelated Caucasian individuals living in Estonia. 
 
 








Number of participants 32 23 43 
Gender, n 
   Male 










Age range (y) 22–57 19–60 20–65 
Mean age±SD (y) 36.9±10 35.9±12.4 46.9±11.8 
Mean duration of disease±SD (y) – 15.6±11.3 23.4±11.2 
Activity of vitiligo, n 
   Active 





Body surface area affected by vitiligo, n 
   <10% 





Patients with psoriatic arthitis, n – – 13 (30.2%) 
Patients with psoriatic nail involvement, n – – 33 (76.7%) 
Onset of psoriasis, n 
   Early onset psoriasis 
   Late onset psoriasis 
– –  
37 (86%) 
6 (14%) 
PASI range – – 2–44 
PASI, n 
   <12 
   ≥12 




The patients with non-segmental vitiligo were enrolled from the outpatient 
department of the Dermatology Clinic. The diagnosis of vitiligo was based on 
the occurrence of depigmented macules on the skin with the typical localisation. 
Depigmentation was confirmed with a Wood’s lamp. Eight of the vitiligo 
patients had active and 15 had stable vitiligo. In the patients with active vitiligo, 
the development of new lesions or the extension of old lesions manifested in 
three months before the examination. None of the patients had received any 
treatment for their vitiligo for at least a month before their recruitment. 
The patients with a clear clinical diagnosis of plaque psoriasis were recruited 
at the outpatient or inpatient department of the Dermatology Clinic. Concomi-
tant psoriatic arthritis was diagnosed in 13 patients. Nail involvement was pre-
sent in 33 patients. Early onset psoriasis, occurring before the age of 40, was 
diagnosed in 37 patients. PASI was calculated and it ranged from 2–44. None of 
the patients had received any treatment for their psoriasis for at least a month 
before their recruitment. 
The control individuals were recruited from among healthcare personnel, 
medical students and patients who turned to the dermatological outpatient clinic 
for the surgical excision of a nevus. None of the control individuals had any 
history of chronic skin diseases nor vitiligo or psoriasis in their family. 
 
 
7.3. Data collection 
7.3.1. Collection of clinical information 
A questionnaire about the age, gender, nationality, skin phototype, comorbi-
dities and diseases in the family was filled by a dermatovenereologist for all 
participants. Information about the onset and course of vitiligo or psoriasis was 
collected. An objective status was assessed in the vitiligo and psoriasis patients. 
The body surface area (BSA) affected by vitiligo was measured and PASI was 
calculated for the patients with psoriasis. 
 
 
7.3.2. Collection of material 
For RNA purification (Paper I, II, III) and immunofluorescence microscopy 
(Paper I, II), two skin punch biopsy samples (3–4 mm in diameter) were 
collected from the patients with vitiligo and psoriasis, one from the marginal 
zone of the lesional skin (hereinafter called lesional skin) and another from the 
non-sun-exposed non-lesional skin. From the patients with psoriasis, punch 
biopsy samples from the lesional and non-lesional skin were also gathered for 
Caspase-1 assay (Paper II). For in situ hybridisation (ISH), one punch biopsy 
sample was taken from the lesional skin of the vitiligo patients (Paper III). From 
the control individuals, one skin punch biopsy sample (3–4 mm in diameter) 
from non-sun-exposed skin was taken for RNA analysis, immunofluorescence 
microscopy, Caspase-1 assay as well as for ISH (Paper I, II, III). Skin samples 
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taken for RNA extraction were instantly frozen in liquid nitrogen or in dry ice 
and stored at -80°C until further experiments (Paper I, II, III). For immuno-
fluorescence microscopy (Paper I, II), Caspase-1 Assay (Paper II) and ISH 
(Paper III), skin biopsy specimens were embedded into the Tissue-Tek (Thermo 
Scientific, Waltham, MA, USA) before freezing. 
Each study participant gave 16 ml venous blood, which was collected into 
BD Vacutainer® CPT™ Cell Preparation Tubes with sodium heparin (BD 
Biosciences, Franklin Lakes, NJ, USA). The plasma was collected for cytokine 
testing (Paper I, II). 
Different skin cell types, including pooled normal human epidermal 
keratinocytes (Promocell, Heidelberg, Germany) (Paper I, III), foreskin-isolated 
melanocytes (Paper I, III) and fibroblasts (Paper I) as well as monocyte derived 
Langerhans cells (moLC) (Paper I) were used for cell culture experiments. 
Melanocytes and fibroblasts were harvested from paediatric foreskin (approval 
number 178/T-19) and cultured as described by Reemann et al. (Reemann et al, 
2014). 
 
7.4. Laboratory methods 
7.4.1. RNA extraction 
For RNA extraction from the skin biopsy samples, the specimens were homo-
genised by a gentleMACSTM Dissociator (Miltenyi Biotec, Heidelberg, Germa-
ny) using M tubes and 700 µl of the QIAzol Lysis Reagent (Qiagen, Valencia, 
CA, USA) or using Precellys24 (Bertin, Montigny-le-Bretonneux, France) 
(Paper I, II, III). 
Total RNA from skin was isolated by using RNeasy Fibrous Tissue Mini Kit 
(Qiagen) or miRNeasy Mini Kit (Qiagen) (Paper I, II, III). For RNA extraction 
from the cells, QIAzol Lysis Reagent (Qiagen) was directly added to the cells 
and total RNA was isolated using the miRNeasy Mini Kit (Qiagen) (Paper I, 
III). The concentration and quality of the RNA were assessed with a NanoDrop 
ND-1000 spectrophotometer (Thermo Fisher Scientific, Wilmington, MA, 
USA) (Paper I, II, III). 
 
 
7.4.2. Cell culture, stimulation and transfection 
Pooled, normal human epidermal keratinocytes (Promocell, Heidelberg, Ger-
many) were cultured in a Keratinocyte-serum-free medium (SFM) with supple-
ments (Life Technologies, Grand Island, NY, USA) (Paper I, III). Melanocytes 
and fibroblasts were isolated and cultured as described by Reemann et al 
(Reemann et al, 2014) (Paper I, III). MoLCs were generated as follows. PBMCs 
were isolated from a buffy coat by Ficoll-Hypaque Plus (Amersham Bio-
sciences, Piscataway, USA) density gradient centrifugation. Monocytes were 
isolated using MACS® anti-CD14 beads (Miltenyi Biotec, Bergisch Gladbach, 
Germany) according to the manufacturer’s protocol up to purity over 95%. The 
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isolated cells were cultured in RPMI 1640 medium supplemented with 10% 
fetal calf serum, 1% penicillin and streptomycin (PAA Laboratories, Pasching, 
Austria) at a density of 1–1.5×106 cells/ml. MoLC were differentiated for seven 
days in the presence of granulocyte-macrophage-colony stimulating factor 
(GM-CSF) (50 ng/ml), IL-4 (25 ng/ml), TGF-β (10 ng/ml) and thymic stromal 
lymphopoietin (TSLP) (5 ng/ml) (R&D Systems, Minneapolis, USA) (Geiss-
mann et al, 1998) (Paper I). 
For two-dimensional (2D) cultures, keratinocytes with the density of 2x104 
cells per well on 24-well plates were seeded; for 3D keratinocyte culture in the 
air-liquid interface, 5×104 cells per well were seeded on ThinCert Cell Culture 
Inserts (0.4μm pore, 0.33 cm2) (Greiner Bio-One, Kremsmünster, Austria). For 
the 3D culture, Keratinocyte-SFM medium with supplements and Dulbecco’s 
Modified Eagle Medium (Life Technologies) containing High Glucose, 
GlutaMAX™ and Pyruvate in 1:1 ratio were used. For the 2D culture, Keratino-
cyte-SFM medium with supplements (Life Technologies) was used (Paper I).  
For cell stimulation, 2×104 melanocytes and keratinocytes per one well in a 
24-well plate were seeded for each stimulation for 5 h, 24 h and 48 h with  
10 ng/ml of TNF-α, 20,000 U/ml of IFN-α2a, 20,000 U/ml of IFN-γ and  
10 ng/ml of IL-1β (Paper III).  
For transfections, 2×104 melanocytes in 1ml of Medium 245CF supple-
mented with the Human Melanocyte Growth Supplement-2 (Life Technologies) 
or 2×104 keratinocytes in 1ml of the Keratinocyte-SFM medium (Life Techno-
logies) were seeded per one well in a 12-well plate. After 24 hours, the cells 
were transfected with the miRIDIAN microRNA hsa-miR-155-5p mimic and 
miRIDIAN microRNA Mimic Negative Control #1 (GE Healthcare Life 
Sciences, Fairfield, CT, USA) at the final concentration of 60 nM using siPORT 
NeoFX (Life Tecnologies) according to the manufacturer’s protocol. When 
indicated, after 24 h, the transfected melanocytes and keratinocytes were 




All amplifications and analyses were carried out on the ViiATM 7 Real-Time 
PCR system (Life Technologies, Grand Island, NY, USA). The relative gene 
expression levels were calculated using the comparative Ct (∆∆Ct) method 
(Livak & Schmittgen, 2001). 
For analysing mRNA expression in the skin samples, cDNA was synthesised 
from 5 μg of total RNA using oligo-dT and SuperScript® III Reverse Tran-
scriptase (Life Technologies) according to the manufacturer’s protocols. For 
PCR, SYBR® Green master mix (Life Technologies) was used. Data were 
normalised to the housekeeping gene ACTB expression. The names of the genes 
are listed in Table 2 (Paper I, II, III). 
To measure mRNA levels in melanocytes and keratinocytes, cDNA was 
synthesised from 100 to 900 ng of total RNA using oligo-dT, RevertAid 
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Reverse Transcriptase, deoxyribonucleotide triphosphates, reaction buffer and 
RiboLock RNase Inhibitor from Thermo Fisher Scientific. qRT-PCR was per-
formed using 5 HOT FIREPol EvaGreen qPCR Supermix (Solis BioDyne, 
Tartu, Estonia). EEF1A1 was used as a housekeeping gene (Paper III). The 
primers were designed with the assistance of Primer 3 and were ordered from 
TAG Copenhagen (Copenhagen, Denmark) (Paper III). 
 
 
Table 2. List of the genes studied by qRT-PCR (Paper I, II, III) 
Short name Long name 
ACTB actin beta 
AIM2 absent in melanoma 2 
CASP1 caspase-1 
CCL2 C-C motif chemokine ligand 2 
CCL5 C-C motif chemokine ligand 5 
CCL20 C-C motif chemokine ligand 20 
CCL27 C-C motif chemokine ligand 27 
CTLA4 cytotoxic T-lymphocyte associated protein 4 
CXCL1 C-X-C motif chemokine ligand 1 
CXCL2 C-X-C motif chemokine ligand 2 
CXCL8 C-X-C motif chemokine ligand 8 
CXCL10 C-X-C motif chemokine ligand 10 
EEF1A eukaryotic translation elongation factor alpha 1** 
EOMES eomesodermin 
FOXP3 forkhead box 3 
IFIH1 interferon induced with helicase C domain 1 
IFITM1 interferon-induced transmembrane protein 1** 
IFNAR1 interferon alpha and beta receptor subunit 1 
IFNG interferon gamma 
IFNGR interferon gamma receptor 1 
IL10 interleukin 10* 
IL17A interleukin 17A 
IL17F interleukin 17F 
IL1B interleukin 1 beta 
IL36A (alias IL1F6) interleukin 36, alpha 
IL1RN interleukin receptor antagonist 
IL20RA interleukin 20 receptor subunit alpha 
IL22 interleukin 22 
IL22RA1 interleukin 22 receptor subunit alpha 1 
IL22RA2 interleukin 22 receptor subunit alpha 2 
IL26 interleukin 26* 
IRF1 interferon regulatory factor 1** 
KLRK1 killer cell lektin like receptor K1 
LCN2 lipocalin 2* 
MEF2A myocyte enhancer factor 2A** 
MICB MHC class I polypeptide-related sequence B 
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Short name Long name 
NLRP1 NLR family pyrin domain containing 1 
NLRP3 NLR family pyrin domain containing 3 
PI3 peptidase inhibitor 3* 
PYCARD PYD and CARD domain containing 
SDCBP syndecan binding protein** 
SOCS1 suppressor of cytokine signalling 1** 
SOX10 SRY (sex determining region Y)-Box 10** 
S100A8 S100 calcium binding protein A8* 
S100A9 S100 calcium binding protein A9* 
TNF tumour necrosis factor 
TRGC1 T cell receptor gamma constant 1 
TYRP1 tyrosine-related protein 1** 
WIPI1 WD repeat domain, phosphoinositide interacting 1 
YWHAE tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein epsilon 
* measured only in the skin from the psoriasis patients comparatively to the skin from 
the control individuals (Paper II) 
** measured only in melanocytes and keratinocytes (Paper III)
 
 
MiRNA expression was analysed with TaqMan miRNA qRT-PCR assays (Life 
Technologies) according to the manufacturer’s protocol with few modifications. 
Briefly, miRNA specific cDNAs were synthesised using the TaqMan MicroRNA 
Reverse Transcription Kit using 10 ng of the total RNA in a 5 μl reaction mix, 
out of which 2.5 μl was used per 10 μl of total qPCR mix containing additio-
nally TaqMan® MicroRNA Assays (Thermo Fisher Scientific) and 5x HOT 
FIREPol® Probe qPCR Mix Plus (ROX) (Solis BioDyne). For normalisation, 
the let-7a was chosen as one of the most common housekeeping miRNAs, with 
Ct values between 20.2 and 22.1 across all skin samples (Paper III). 
 
 
7.4.4. Immunofluorescence assay 
Immunofluorescence assay was conducted on 5 μm thick frozen sections of the 
skin biopsy samples. The skin sections were fixed with 4% formaldehyde, 
permeabilised with 0.2% Triton X-100 in phosphate-buffered saline (PBS) and 
blocked with the normal goat serum and bovine serum albumin (Paper I, II). 
After that, the Alexa Fluor 594 Tyramide SuperBoost Kit (Thermo Fisher 
Scientific, Wilmington, MA, USA) was used for signal amplification. Skin 
sections of the patients with vitiligo were incubated with mouse monoclonal 
antibodies for LC3 (nanoTools, Teningen, Germany) and mouse anti-human 
major histocompatibility complex (MHC) class I polypeptide-related sequence 
A (MICA)/MICB antibodies (BioLegend, San Diego, CA, USA). Next, the 
slides were incubated with the poly-horseradish peroxidase (HRP) conjugated 
goat anti-mouse secondary antibody. For signal enhancement, the tyramide 
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working solution was added and the stop solution was used to halt the HRP 
reaction. To identify melanocytes, the skin sections were incubated with anti-
tyrosinase related protein 1 (TYRP1) rabbit polyclonal antibodies (Atlas Anti-
bodies, Sweden) and incubated with the Alexa Fluor® 488 conjugated Goat 
anti-Rabbit IgG (H+L) Secondary Antibody (1:1,000, ThermoFisher Scientific, 
1:500) (Paper I). The antibodies used on the skin sections gathered from the 
patients with psoriasis were CD3 (mouse anti-human, Alexa Fluor 488-con-
jugated, UCHT1, Biolegend) and eomesodermin (EOMES) (rabbit polyclonal, 
Novus Biologicals). After incubation with antibodies, the skin slides were 
washed in PBS, and incubated with Alexa Fluor 594-conjugated F(ab’)2-goat 
anti-rabbit IgG (H+L) cross-adsorbed secondary antibodies (ThermoFisher 
Scientific, 1:500) (Paper II). All of these antibodies were used on the control 
skin (Paper I, II). For nuclear staining 4′,6-diamidine-2′-phenylindole dihydro-
chloride (DAPI) (1 μg/mL) was used. After that, the slides were washed in PBS 
and covered with a fluorescent mounting medium (Dako, Santa Clara, CA, 
USA) and coverslips (Paper I, II). The images were obtained with the FV1200 
(Olympus, Tokyo, Japan) (Paper I) or LSM710 (Zeiss, Wetzlar, Germany) con-
focal microscope (Paper II). For the quantification of the fluorescence signal, 
marking LC3 and DAPI, Fiji (Schindelin et al, 2012) with built-in options was 
used (Paper I). 
 
 
7.4.5. Caspase-1 assay 
Caspase-1 activation was assessed in the lesional and non-lesional psoriatic skin 
and the control skin cryosections with the FAM-FLICATM Caspase-1 Assay Kit 
(ImmunoChemistry Technologies, Bloomington, MN, USA) according to the 
manufacturer’s manual. Briefly, 5 μm cryosections of the skin biopsy speci-
mens were fixed with acetone and washed twice with PBS. For blocking, the 
10% normal goat serum (Thermo Fisher Scientific) and 0.5% bovine serum 
albumin in PBS were used. The caspase-1 activity was determined by incu-
bating with the fluorochrome-labelled inhibitor of caspases (FLICA) Caspase-1 
Reagent (FAM-YVAD-FMK) followed by washing steps. The nuclei were 
stained with Hoechst 33342 (2′-[4-ethoxyphenyl]-5-[4-methyl-1-piperazinyl]-
2,5′-bi-1H-b enzimidazole trihydrochloride trihydrate). The slides were covered 
with the Fluorescence Mounting medium (Dako, Santa Clara, CA, USA) and 
analysed with the Leica DM5500 B microscope (Leica Microsystems, Wetzlar, 
Germany). The green fluorescence signal, indicating the activity of caspase-1, 
was quantified with the help of Fiji (ImageJ)64 in fixed areas of the stratum 
spinosum. Cell nuclei were counted in the same fixed areas and the fluorescence 




7.4.6. miR-155 in situ hybridisation 
ISH was optimised and performed on 10 µm frozen sections of the lesional and 
non-lesional vitiligo skin as well as the control skin using the microRNA ISH 
Buffer and Controls Kit according to the manufacturer’s instructions. For the 
detection of miR-155, the miRCURY LNA™ Detection Probe for hsa-miR-155 
(88072-15) (Exiqon, Vedbaek, Denmark) was used. Prehybridisation, hybridisa-
tion and washings were performed at 50°C. The slides were incubated with a 
sheep anti-digoxigenin alkaline phosphatase conjugate (1:1,500, Roche, Basel, 
Switzerland) and stained by adding the BM Purple AP Substrate (Roche, 
Pleasanton, CA, USA). The nuclei were stained with the Nuclear Fast Red 
counterstain (Vector Laboratories, Burlingame, CA, USA). The images were 
obtained with the Leica DM5500 B microscope (Leica Microsystems, Wetzlar, 
Germany) (Paper III). 
 
 
7.4.7. Cytokine testing 
For separating the plasma from the blood cells, the blood tubes were centri-
fuged at 1,500 g for 30 minutes. The plasma was collected and stored at -20˚C. 
Similarly to the control individuals, the concentration of TNF-α, IL-1β, IL-
1Ra/IL-1F3, IL-2, IL-5, IL-6, IL-8/CXCL8, CXCL10/IP-10, IFN-γ, Granulo-
cyte–Colony Stimulating Factor (G-CSF) and GM-CSF was measured in the 
heparin treated plasma of the vitiligo patients (Paper I). From the plasma of the 
psoriasis patients, the levels of TNF-α, IL-1β, IL-1Ra/IL-1F3, IL-2, IL-5, IL-6, 
IL-7, IL-8/CXCL8, IL-10, IL-17A, IL-17F, IL-22, IL-31, IL-33, IL-36β, IFN-γ, 
CXCL10/IP-10, G-CSF, GM-CSF, and Lipocalin-2/NGAL were measured 
(Paper II). The xMAP technology on Luminex 200 (Luminex Corporation, 
Austin, Texas, USA) was used. The Milliplex MAP multiplex assay was 
conducted in a 96-well microplate format according to the manufacturer’s 
instructions (Millipore, Billerica, MA, USA) (Paper I, II). 
 
 
7.5. MiRNA target selection and pathway analysis 
Putative targets for miRNAs were identified using the Targetscan 6.2 
(http://www.targetscan.org/) (Friedman et al, 2009). Only highly conserved 
targets with a total context score below -0.15 were chosen. For the pathway 
analysis, the genes expressed in the skin according to the previously published 
(Rebane et al, 2012) dataset E-MTAB-729 (9,966 genes with an average signal 
>40.0 in the skin from healthy individuals) were selected. The pathway analysis 
was conducted using the g:Profiler (http://biit.cs.ut.ee/gprofiler) (Reimand et al, 
2007). To estimate the significance of the overlap between the target genes and 
the indicated functional group, the Fisher exact test was used (Paper III). 
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7.6. Biostatistics and data visualisation 
Statistical analysis was performed using the statistical software R (https:// 
www.r-project.org/) (Paper I, II) or GraphPad Prism 5 (GraphPad Software, San 
Diego, CA, USA) (Paper III). The mRNA expression values and the fluore-
scence signal ratios in Papers I and II were log-transformed before the statistical 
testing in order to adhere to the assumptions of the normal distribution. The 
conformity to the normal distribution was assessed using the Kolmogorov–
Smirnov test. Comparisons between the vitiligo patients and the control 
individuals were made using an unpaired Student’s t-test (Paper I) and a paired 
Student’s t-test or the Mann-Whitney U test (Paper III). The paired t-test was 
used, since it is required for comparing lesional and non-lesional skin. In Paper 
III, the results of the paired t-test did not differ significantly from the results 
gained with the unpaired Student’s t-test. When comparing the vitiligo lesional 
skin with non-lesional skin (Paper I, III) or the expression of genes in cell 
cultures (Paper I, III), the paired Student’s t-test was used. In the mRNA 
expression analysis and immunofluorescence signal quantification, if the 
vitiligo lesional and non-lesional skin was compared to the healthy control skin, 
Dunnett’s correction was applied to adjust for multiple comparisons (Paper I). 
The mean and standard deviations of the log-transformed mRNA expression 
values were back-transformed to a linear scale for plotting, which is shown as 
the geometric mean ×÷ the geometric standard deviation on the graphs (Paper 
I). For comparing the lesional and non-lesional psoriatic skin and the control 
skin, the Linear Models for Microarray and RNA-Seq Data (limma) R package 
ver. 3.28.21 from Bioconductor (Ritchie et al, 2015) was used (Paper II). A p-
value < 0.05 was considered significant. 
To compare cytokine concentrations in the plasma of the vitiligo patients 
and control individuals, the unpaired Student’s t-test was used, since the data 
approximately followed a normal distribution (Paper I). To identify statistically 
significant differences in the concentration levels of cytokines in the psoriasis 
patients and control individuals, the values were log2-transformed and the 
Wilcoxon signed-rank test was used. The results were considered significant at 
p-value < 0.05. Comparisons of the selected phenotypes in the plasma samples 
of the psoriasis patients were performed using multi-factor ANOVA, followed 
by Tukey’s multiple comparison test to find the groups that were significantly 
different from each other. Results were then filtered based on the adjusted p-
value ≤ 0.05. A phenotype comparison was carried out for the differentially 
expressed plasma cytokines which showed statistically significant changes 
between the psoriasis patients and the control group (Paper II).  
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8. RESULTS 
8.1. Inflammatory markers are modestly upregulated 
among the patients with vitiligo (Paper I) 
To study inflammation in the vitiligo skin, we measured the relative expression 
of genes encoding inflammatory cytokines, receptors and the components of 
inflammasomes in the lesional and non-lesional skin of 16 vitiligo patients (4 
males, 12 females, ages ranging from 19–60 years) and 24 control individuals 
(8 males, 16 females, ages ranging from 24–57 years). From cytokines, only 
TNF was significantly upregulated both in the vitiligo lesional (adjusted p < 
0.05) and non-lesional skin (adjusted p < 0.05) (Figure 6A). The expression of 
IL36A (alias IL1F6) (adjusted p < 0.05), CCL5 (adjusted p < 0.05) and CXCL10 
(adjusted p < 0.001) was increased exclusively in the vitiligo lesional skin. 
Solely in the vitiligo non-lesional skin, IL1RN (adjusted p < 0.05) was up-
regulated. Comparing the vitiligo lesional skin with the non-lesional skin, the 
CCL27 expression was higher in the lesional skin (adjusted p < 0.05) (Figure 
6A). The transcripts of IFNG and Th17 specific cytokines (IL17A, IL17F, IL22) 
remained undetectable in the control as well as in the vitiligo biopsy samples 
(data not shown). Despite this, similarly to the IFN-induced chemokine 
CXCL10, IFN-induced innate immune receptor IFIH1 was upregulated in the 
vitiligo lesional skin (adjusted p < 0.01) (Figure 6B). Furthermore, the IFIH1 
expression was also increased in the non-lesional skin taken from the vitiligo 
patients (adjusted p < 0.05). The highly significant upregulation of IL22RA1 
(adjusted p < 0.05) was detected in the vitiligo non-lesional skin (Figure 6B). 
From the studied inflammasome-related genes, only AIM2 was slightly elevated 
in the vitiligo non-lesional skin (adjusted p < 0.05) (Figure 6C). We also com-
pared the gene expression between the patients with an active (5 patients) and a 
stable (11 patients) form of the disease; however, the data did not reveal a 





Figure 6. The relative expression of mRNAs encoding (A) cytokines, (B) receptors and 
(C) components of the inflammasome in the skin of the control individuals (CS), and in 
the lesional (VLS) and non-lesional skin (VNLS) of the vitiligo patients. The geometric 
mean ×÷ the geometric standard deviation is indicated. *p < 0.05; **p < 0.01; ***p < 
0.001. 
 
To check for possible signs of a systemic inflammation, we measured the con-
centration of inflammation-associated cytokines in the plasma of 18 vitiligo 
patients (5 males, 13 females, ages ranging from 19–60 years) and 24 control 
individuals (8 males, 16 females, ages ranging from 24–57 years). We found 
lower plasma concentrations of the IL-1 inhibitor IL1-Ra (p < 0.05) and G-CSF 






Figure 7. The concentration of cytokines in the plasma of the control individuals (C) 
and vitiligo patients (V). The arithmetic mean ± the standard deviation is indicated. *p < 
0.05; **p < 0.01. 
 
8.2. Markers of innate cell infiltration are dysregulated in 
the vitiligo skin (Paper I) 
Next, we studied immune cell infiltration to vitiligo lesions based on the cell-
type specific gene expression in skin. The expression of the T cell inhibitor 
CTLA4 was increased in the vitiligo lesional (adjusted p < 0.001) and non-
lesional skin (adjusted p < 0.001) (Figure 8A). Moreover, EOMES, a tran-
scription factor characteristic of effector cytotoxic T cells, unconventional 
memory CD8+ T cells and NK cells (Collins et al, 2017; Jacomet et al, 2015; 
Martinet et al, 2015; White et al, 2016), was increased in both the vitiligo 
lesional (adjusted p < 0.001) and non-lesional skin (adjusted p < 0.001) (Figure 
8A). KLRK1, encoding the activating NK cell receptor NKG2D, and TRGC1, 
which encodes a T cell receptor γ-chain, showed a tendency for an increased 
expression in the vitiligo lesional skin compared to that in healthy skin (ad-
justed p = 0.055 and p = 0.058, respectively) (Figure 8A). Notably, the stress 
molecule MICA/MICB, which can be bound by activating NK cell receptors 
(Ghadially et al, 2017), also showed a tendency for an increased expression in 
vitiligo lesions (adjusted p = 0.052) (Figure 8A). Next, we performed MICA/ 
MICB immunofluorescence staining on sections from three vitiligo (1 male, 2 
females, ages ranging from 28–47 years) and three control (3 females, ages 
ranging from 22–38 years) biopsy samples together with the melanocyte marker 
TYRP1 (Figure 8B). While the control skin and the vitiligo non-lesional skin 
were completely clean of MICA/MICB, we noted multiple positive cells in the 
sub-epidermal area of the vitiligo lesional skin. Often, the stained cells had a 
disturbed nuclear morphology, as can be seen in the middle panel of Figure 8B. 




Figure 8. (A) The relative mRNA expression of the genes encoding the markers of the 
infiltrating immune cells and their target molecules. The geometric mean ×÷ the 
geometric standard deviation is indicated. ***p < 0.001. (B) An immunofluorescence 
image of MICA/MICB (MHC class I chain-related protein A and B) and TYRP1 
(tyrosinase related protein 1) in sections of the biopsy samples from the control 
individuals (CS), and in the lesional (VLS) and non-lesional skin (VNLS) of the vitiligo 
patients. DAPI (4′,6-diamidine-2′-phenylindole dihydrochloride) counterstains cell 
nuclei. 
 
8.3. Hallmarks of autophagy are altered  
in the vitiligo skin (Paper I) 
The gene WIPI1, regulating autophagy and melanosome maturation (Akinduro 
et al, 2016; Ho et al, 2011), was significantly downregulated in both the lesional 
(adjusted p < 0.01) and non-lesional (adjusted p < 0.001) skin taken from the 
patients with vitiligo (Figure 9A). We compared the WIPI1 mRNA expression 
levels in various cell types present in the skin and found the highest expression 
level in melanocytes, followed by fibroblasts (Figure 9B). The WIPI1 expres-
sion was relatively low in the moLCs and keratinocytes in a 2-dimensional 
culture but the expression increased during the differentiation of keratinocytes 
at the air-liquid interface (Figure 9B). To determine if the WIPI1 downregula-
tion in the vitiligo skin can be associated with impaired autophagy in melano-
cytes, we stained the tissue sections of the skin biopsy samples for LC3, a 
marker of autophagy (Mizushima et al, 2010) (Figure 9C). When autophagy is 
initiated, the cytosolic form of LC3 is conjugated with phosphatidylethanol-
amine, a cell membrane phospholipid, to form a lipidated LC3 conjugate, which 
is recruited to autophagosomal membranes. This is associated with the con-
version of the dim homogenous fluorescence into a dotted pattern in the cytosol 
(Mizushima et al, 2010). In the control skin and in the vitiligo non-lesional skin, 
most of the melanocytes were devoid of LC3 dots, whereas in the vitiligo 
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lesions, the scarce remaining melanocytes with weak TYRP1 staining showed 
an LC3 pattern characteristic to autophagy (Figure 9C). Keratinocytes in the 
vitiligo lesions also had significantly more autophagic vacuoles throughout all 
the layers of the epidermis, in comparison to the control and non-lesional skin 





Figure 9. (A) WIPI1 relative mRNA expression in the skin of the control individuals 
(CS), and in the lesional (VLS) and non-lesional skin (VNLS) of the vitiligo patients. 
The geometric mean ×÷ the geometric standard deviation is indicated. **p < 0.01; ***p 
< 0.001. (B) WIPI1 relative mRNA expression in various cell types of the skin. The 
geometric mean ×÷ the geometric standard deviation is indicated. 2D, two-dimensional; 
ALI, air-liquid interface; moLC, monocyte derived Langerhans cells. (C) An immuno-
fluorescence image of LC3 (microtubule-associated protein light chain 3) and TYRP1 
(tyrosinase related protein 1) in sections of the biopsy samples from the control 
individuals (CS), and in the lesional (VLS) and non-lesional skin (VNLS) of the vitiligo 
patients. DAPI (4′,6-diamidine-2′-phenylindole dihydrochloride) counterstains cell nuclei. 
The white bar represents 5 μm. (D) The immunofluorescence image as in panel C with 
the white bar representing 20 μm. Neg. refers to a control slide with secondary anti-
bodies only. (E) The box-and-whisker plots show the median and interquartile range of 
the ratio between the fluorescence signal marking the LC3 expression and DAPI (cell 
nuclei) in CS, VNLS and VLS. Whiskers cover data points within a 1.5× interquartile 
range. *p < 0.05. 
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8.4. Inflammatory cytokines, chemokines and 
antimicrobial peptides are upregulated, but CCL27 is 
downregulated in psoriatic lesions (Paper II) 
In order to assess inflammation in the psoriatic skin, we conducted a gene 
expression analysis in the lesional and non-lesional skin of 33 psoriasis patients 
(23 males, 10 females, ages ranging from 20–63 years) and 23 control indivi-
duals (8 males, 15 females, ages ranging from 24–57 years). We found that the 
Th17 cytokine gene expression (IL17A, IL17F, IL22, IL26) was significantly 
increased in the psoriatic lesional skin in comparison to the non-lesional and 
control skin (adjusted p < 0.001 for all these comparisons) (Figure 10A). The 
mRNA of other proinflammatory cytokines, IFNG, TNFA, IL1B and IL36A 
(alias IL1F6), was also markedly elevated in the psoriatic lesional skin in com-
parison to the control skin (adjusted p < 0.001 in all comparisons) and the 
psoriasis non-lesional skin (adjusted p < 0.001 in all comparisons except the 
case of TNFA). From these cytokines, IL36A was additionally upregulated in 
the psoriasis non-lesional skin (adjusted p = 1.70×10–5) (Figure 10A). The 
expression of chemokines CXCL1, CXCL2, CXCL8, CXCL10, CCL2, CCL5 and 
CCL20 was significantly elevated in the lesional skin of the psoriasis patients 
(adjusted p < 0.001 for all comparisons) and the expression of CXCL10 
(adjusted p = 0.002) and CCL20 (adjusted p = 0.022) was also upregulated in 
the psoriasis non-lesional skin (Figure 10B). Only CCL27 was significantly 
downregulated in the psoriatic skin (adjusted p < 0.001). With regard to cyto-
kine receptors, only IL22RA1 showed elevated mRNA signals in the psoriatic 
skin (adjusted p < 0.001) (Figure 11). Antimicrobial peptides S100A8, S100A9, 
PI3 and LCN2 were significantly upregulated in the psoriatic skin (adjusted p < 





Figure 10. The relative expression of mRNAs encoding (a) inflammatory cytokines and 
(b) chemokines in the skin biopsy samples obtained from the lesional (L) and non-
lesional (NL) skin of the psoriasis patients as well as from the control individuals (C). 
The box-and-whisker plots depict the median (central line), interquartile range (IQR, 
Q1-Q3, box), Q3 + 1.5 × IQR (upper whisker) and Q1 − 1.5 × IQR (lower whisker). 
Stars above the groups C and NL depict their significance level from L samples.  
*p < 0.05, **p < 0.001. Grey shading behind the gene name indicates statistically 
significant differences between the NL and C biopsy samples (for IL36A p = 1.70×10-5, 




Figure 11. The relative mRNA expression of several cytokine receptors in the skin 
biopsy samples obtained from the lesional (L) and non-lesional (NL) skin of the 
psoriasis patients as well as from the control individuals (C). The box-and-whisker plots 
depict the median (central line), interquartile range (IQR, Q1-Q3, box), Q3 + 1.5 × IQR 
(upper whisker) and Q1 – 1.5 × IQR (lower whisker). Stars above the groups C and NL 
depict their significance level from L samples. ** p < 0.001. Grey shading behind the 
gene name indicates statistically significant differences between the NL and C biopsy 




Figure 12. The relative mRNA expression of several antimicrobial peptides in the skin 
biopsy samples obtained from the lesional (L) and non-lesional (NL) skin of the 
psoriasis patients as well as from the control individuals (C). The box-and-whisker plots 
depict the median (central line), interquartile range (IQR, Q1-Q3, box), Q3 + 1.5 × IQR 
(upper whisker) and Q1 – 1.5 × IQR (lower whisker). Stars above the groups C and NL 





8.5. Innate receptors and inflammasome components are 
dysregulated in the psoriatic skin (Paper II) 
Next, we studied components of the autophagosome (WIPI1) and several innate 
receptors (IFIH1, AIM2) and inflammasome components (AIM2, NLRP1, 
NLRP3, PYCARD, CASP1) in the skin of psoriasis patients in comparison to 
control individuals. The WIPI1, NLRP1, NLRP3 and CASP1 expression levels 
were not significantly different in the studied groups (data not shown). How-
ever, the IFIH1 (adjusted p < 0.001), AIM2 (adjusted p < 0.001) and PYCARD 
(adjusted p < 0.001) genes showed an increased expression in the psoriatic 
lesional skin (Figure 13A). To determine whether the elevated expression of 
inflammasome components (AIM2, PYCARD) could be associated with the 
increased inflammasome activation and active caspase-1 accumulation in the 
psoriatic lesions, we used the FLICA reagent, which forms a covalent bond with 
active caspase-1. The lesional and non-lesional skin from two psoriasis patients 
(2 males, 47 and 65 years old) and the skin from two control individuals (2 
females, 39 and 51 years old) was used for the assay. The FLICA staining of the 
healthy skin cryosections localised exclusively to the epidermis with the highest 
signals in the granular layer (Figure 13B). While the psoriatic non-lesional skin 
(Figure 13C) did not substantially differ from the healthy control skin, FLICA 
staining was detectable throughout the thickened psoriatic epidermis in the 
lesional skin and covered some dermal areas close to the epidermis (white 
arrow in Figure 13D). Due to the intercellular oedema in the psoriatic 
epidermis, the number of cells per fixed section area was lower, and therefore 
the green fluorescence intensity per keratinocyte was significantly higher in 
psoriatic lesions (p < 0.05) in comparison to the healthy skin or non-lesional 





Figure 13. (a) The relative mRNA expression of genes encoding innate receptors in the 
skin biopsy samples obtained from the lesional (L) and non-lesional (NL) skin of the 
psoriasis patients and from the control individuals (C).  The box-and-whisker plots 
depict the median (central line), interquartile range (IQR, Q1-Q3, box), Q3 + 1.5 × IQR 
(upper whisker) and Q1 – 1.5 × IQR (lower whisker). Stars above the groups C and NL 
depict their significance level from L samples. ** p < 0.001. (b–e) Fluorescence 
microscopic images illustrate caspase-1 activation as detected with the FAM-FLICA 
Assay Kit (green) in the control skin (b), psoriatic non-lesional skin (c) and psoriatic 
lesional skin (d) biopsy frozen sections with DAPI for counterstaining cell nuclei. (e) 
Represent control slides. White bars in the 20x images represent 75 μm. The white 
dotted lines indicate the basal membrane. (f) Green fluorescence intensity was measured 
from the slides in fixed areas of the stratum spinosum (from the slides of two different 
individuals and 2–3 different areas per slide) and divided by the number of cells in that 
area. *p < 0.05, ** p < 0.001. 
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8.6. Gene expression analysis reveals immune cell 
infiltration to the psoriatic lesional as well as  
non-lesional skin (Paper II) 
Several immunoregulatory genes and marker transcription factors were upregu-
lated in the skin of psoriasis patients in comparison to control individuals 
(Figure 14). Specifically, the expression of CTLA4, FOXP3, IL10 and IL1RN 
was markedly elevated in the psoriatic lesions, while the expression of CTLA4 
and IL10 was elevated also in the non-lesional skin of the psoriasis patients 
(adjusted p < 0.001 in all comparisons) (Figure 14A). We found a moderate 
increase in the stress molecule MICB expression in the psoriatic lesional skin 
(adjusted p < 0.05) (Figure 14B). From the markers of effector cells, only the 
EOMES expression was significantly increased in the psoriatic skin (adjusted p 
< 0.001) as well as the non-lesional skin (adjusted p < 0.001) (Figure 14B). The 
immunofluorescence microscopy of the skin sections from two psoriasis pa-
tients and two control individuals showed that in the psoriatic skin a fraction of 
CD3+ T cells contained eomesodermin in their nuclei (Figure 14C, left panels) 





Stainings: eomesodermin, CD3 and DAPI 
 
Figure 14. The relative mRNA expression of several (a) immunoregulatory genes and 
(b) genes specific for different cytotoxic effector cells in the skin biopsy samples 
obtained from the lesional (L) and non-lesional (NL) skin of the psoriasis patients and 
from the control individuals (C). The box-and-whisker plots depict the median (central 
line), interquartile range (IQR, Q1-Q3, box), Q3 + 1.5 × IQR (upper whisker) and Q1 – 
1.5 × IQR (lower whisker). Stars above the groups C and NL depict their significance 
level from L samples. *p < 0.05; ** p < 0.001. Grey shading behind the gene name 
indicates statistically significant differences between the NL and C samples (p < 0.001). 
(c) Fluorescence microscopic images illustrate CD3 expression (green) and 
eomesodermin staining (red) in the psoriatic lesional skin biopsy frozen sections (left 
panels). The middle panels represent the healthy control skin and the right-hand panels 
the negative control staining (secondary antibodies only). The lower panels include 
DAPI for counterstaining cell nuclei (blue). The white bar represents 10 μm. 
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8.7. Plasma levels of cytokines are consistent with 
systemic inflammation in psoriasis (Paper II) 
To study the signs of systemic inflammation in psoriasis, we measured the con-
centration of several cytokines and chemokines in the plasma samples of 41 
psoriasis patients (31 males, 10 females, ages ranging from 20–63 years) and 23 
control individuals (8 males, 15 females, ages ranging from 24–57 years). The 
levels of IL-17A (p = 3.6x10–5), IL-6 (p = 0.002), TNF-α (p = 0.002), IL-1Ra  
(p = 4.9x10–4) and CXCL8 (p = 4.3x10–5) were significantly higher in the 
plasma of the psoriatic patients in comparison to the control individuals (Figure 
15A). The IL-17A concentration was higher in moderate to severe psoriasis (p = 
0.001), while higher IL-6 levels were associated with joint involvement (p = 




Figure 15. (a) The cytokine and chemokine concentrations in the plasma samples of the 
psoriasis patients (P) and the control individuals (C). (b) A comparison of the 
circulating cytokine levels in the psoriasis patients with different clinical features. The 
box-and-whisker plots depict the median (central line), interquartile range (IQR, Q1-
Q3, box), Q3 + 1.5 × IQR (upper whisker) and Q1 − 1.5 × IQR (lower whisker). 
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8.8. MiRNAs are dysregulated in the vitiligo skin (Paper III) 
To understand the potential role of miRNAs in vitiligo, we measured the 
expression of 12 miRNAs (miR-10a, miR-99b, miR-125a, miR-125b, miR-145, 
miR-146a, miR-146b, miR-155, miR-199a-3p, miR-203, miR-223 and miR-
511) (Table 3) in the lesional and non-lesional skin of 15 vitiligo patients (4 
males, 11 females, ages ranging from 19–60 years) and in the skin of 15 control 
individuals (6 males, 9 females, ages ranging from 25–53 years). The expres-
sion of all these miRNAs was measurable by qRT-PCR in the skin from the 
control individuals (Figure 16A). miR-125b was the most extensively expressed 
miRNA with the expression level approximately 3,800 times higher than that of 
miR-511, the miRNA with the lowest expression level (the average threshold 
cycle being 29.5) (Figure 16A). From the miRNAs examined, miR-99b, miR-
155, miR-199a-3p, miR-125b, miR-145 and miR-146b were aberrantly 
expressed in the skin from the vitiligo patients (Figure 16B). The expression of 
miR-99b was increased in both the vitiligo lesional (p < 0.001) and non-lesional 
skin (p < 0.01). Exclusively in the vitiligo lesional skin, an upregulation of miR-
155 (p < 0.01), miR-199a-3p (p < 0.01), miR-125b (p < 0.05) and a down-
regulation of miR-145 (p < 0.05) was detected. miR-146b (p < 0.05) was 
differentially expressed in the lesional compared to the non-lesional skin from 
the vitiligo patients (Figure 16B). The expression levels of dysregulated 
miRNAs did not differ between the patients with active and stable vitiligo (data 
not shown). We did not detect statistically significant differences in the 
expression levels of miR-10a, miR-125a, miR-146a, miR-203, miR-223 and 





Table 3. The functions of the analysed miRNAs (Paper III) 
miRNA Function References 
miR-10a Regulates the proliferation of different 
cells including keratinocytes 
(Vaher et al, 2019) 
miR-99b Regulates cell proliferation and migration 
through targeting multiple genes in AKT/ 
mTOR signalling 
(Jin et al, 2013) 
miR-125b Regulates the proliferation, differentiation 
and apoptosis in various cell types, 
including keratinocytes 
(Xu et al, 2011) 
Suppresses proliferation and promotes the 
differentiation of keratinocytes by 
targeting FGFR2  
(Xu et al, 2011) 
miR-125a Promotes differentiation; suppresses the 
proliferation and apoptosis of different 
cell types 
(Potenza & Russo, 2013) 
miR-145 Expression is reduced in cultured pigment 
cells after the induction of pigmentation 
(Dynoodt et al, 2013) 
miR-146a, 
miR-146b 
Suppress inflammation through inhibiting 
the NF-kB signalling pathway by targeting 
IRAK1 and CARD10 
(Hermann et al, 2017; 
Rebane et al, 2014) 
Suppress keratinocyte proliferation (Hermann et al, 2017) 
miR-155 Induces inflammation through activating 
IFN signalling by targeting SOCS1 
(Dudda et al, 2013) 
Increases the T cell proliferative response 
by targeting CTLA4 
(Sonkoly et al, 2010) 
miR-199a-3p Regulates the proliferation and 
differentiation of different cell types by 
targeting MTOR and CAV2 
(Fornari et al, 2010; 
Shatseva et al, 2011) 
miR-203 Regulates the differentiation and functions 
of keratinocytes 
(Sonkoly et al, 2007) 
miR-223 Controls innate immune responses by 
targeting NLRP3 
(Rebane & Akdis, 2013) 
miR-511 Regulates the functions of dendritic cells 
and macrophages 







Figure 16. The relative expression of miRNAs in the skin of (A, B) the control 
individuals and (B) the patients with vitiligo. (A) The results in the control skin are 
represented as boxes with whiskers showing the minimum and maximum and are shown 
relative to the level of miR-511 (=1). (B) Selected individual miRNA levels in the skin 
of the control individuals (CS, =1) and in the lesional (VLS) and non-lesional skin 
(VNLS) of the patients with vitiligo. The mean ± the standard error of the mean is 
indicated. *p < 0.05; **p < 0.01; and ***p < 0.001. 
 
8.9. Dysregulated miRNAs in vitiligo have several putative 
targets related to melanocyte functioning (Paper III) 
To examine whether the aberrantly expressed miRNAs (miR-99b, miR-125b, 
miR-145, miR-155, miR-199a-3p) can affect cellular processes associated with 
vitiligo, we conducted a pathway analysis for the conserved and best-scored 
miRNA targets expressed in the skin. We observed that miR-99b, miR-125b, 
miR-155 and miR-199a-3p have predicted direct targets belonging to either the 
Gene Ontology (GO) or Human Phenotype Ontology (HP) groups or to the 
Kyoto Encyclopaedia of Genes and Genomes (KEGG) related to melanocyte 
differentiation, melanogenesis, melanosome structure and localisation, and skin 
pigmentation (Table 4). For miR-145, we identified predictive target genes 
involved in the regulation of stress-activated mitogen-activated protein kinase 

























































































































































































































































































































































































































































































































































































































































































































8.10. miR-155 is upregulated in the vitiligo skin and  
is induced by inflammatory cytokines (Paper III) 
As miR-155 was upregulated in the vitiligo lesional skin, predicted to target 
multiple important melanogenesis associated genes and has previously been 
shown to contribute to the activation of IFN signalling (Wang et al, 2010) 
playing a role in vitiligo pathogenesis (Bertolotti et al, 2014), we focused on 
miR-155 next. To get information about the localisation of miR-155 in the skin, 
we performed ISH on the skin samples from two vitiligo patients (2 females, 18 
and 35 years old) and two control individuals (2 females, 27 and 47 years old). 
The expression of miR-155 was observed in the stratum basale, where melano-
cytes and proliferating keratinocytes are situated, as well as in the stratum 
spinosum of the epidermis of the vitiligo patients. In accordance with the qRT-
PCR results (Figure 16B), no signal in one control skin and a faint positive 
signal of miR-155 in the epidermis of other control skin was detected (Figure 
17A). 
Next, we studied whether proinflammatory cytokines (TNF-α, IFN-γ, IFN-α, 
IL-1β) affect the expression of miR-155 in melanocytes and keratinocytes. 
These cytokines were selected because they are known to be associated with the 
pathogenesis of vitiligo (Bertolotti et al, 2014; Ezzedine et al, 2015a; Reimann 
et al, 2012). In foreskin-isolated melanocytes, miR-155 was significantly up-
regulated by TNF-α, IFN-γ, IFN-α and IL-1β after 24 h (p < 0.001, p < 0.01, 
 p < 0.05 and p < 0.01, respectively) and 48 h (p < 0.001, p < 0.01, p < 0.01 and 
p < 0.001, respectively) of stimulation (Figure 17B). In pooled normal epi-
dermal keratinocytes, the expression of miR-155 significantly increased after 
being treated by TNF-α and IFN-α (p < 0.001 in both cases) for 24 h and then 
decreased (p < 0.01 in both cases) at the 48 h timepoint. In reaction to IFN-γ, 
miR-155 was upregulated after 24 h (p < 0.01) and 48 h (p < 0.05) of stimu-
lation. A significant upregulation of miR-155 by IL-1β was detected only after 




Figure 17. (A) The expression of miR-155 in the skin using in situ hybridisation. Red 
colour indicates nuclear fast red staining, blue colour the miR-155 expression, bar = 50 
μm. The expression of miR-155 in (B) melanocytes and (C) keratinocytes. The 
expression of miR-155 in the tumour necrosis factor (TNF)-α-, interferon (IFN)-γ-, 
IFN-α- and interleukin (IL)-1β-treated melanocytes and keratinocytes is shown relative 
to the expression levels in unstimulated cells at each indicated time-point. Results are 
displayed as the mean ± the standard error of the mean. The data come from three 





8.11. miR-155 inhibits melanogenesis-associated targets 
and modulates interferon-inducible genes in melanocytes 
and keratinocytes (Paper III) 
To determine whether miR-155 may affect the development of vitiligo by 
targeting the melanogenesis-associated and the IFN-regulated genes in the skin, 
we conducted miR-155 overexpression experiments in melanocytes and 
keratinocytes. In order to do so, we transfected human primary melanocytes 
with the miR-155 mimic and the control mimic (Figure 18A). Thereafter we 
stimulated the cells with IFN-γ or left them unstimulated, and measured the 
relative expression of selected putative miR-155 targets associated with 
melanocyte functions and IFN-regulated genes. The genes associated with 
melanogenesis, such as TYRP1, SDCBP, YWHAE (Figure 18B), and a gene 
associated with melanocyte differentiation, SOX10 (Figure 18C), were involved 
in the analysis. From the IFN-γ-inducible genes, we analysed the effect of miR-
155 on IFITM1, IRF1 (Rebane et al, 2012) and the previously described miR-
155 direct target SOCS1 (Figure 18D).  
The overexpression of miR-155 downregulated the expression of TYRP1 (p 
< 0.01), YWHAE (p < 0.01) and SOX10 (p < 0.05) in melanocytes that were left 
unstimulated (Figure 18B, C). The expression level of SDCBP was suppressed 
by miR-155 both in unstimulated (p < 0.01) and IFN-γ-stimulated (p < 0.05) 
melanocytes (Figure 18B). From IFN-inducible genes, SOCS1 was down-
regulated by miR-155 both in unstimulated (p < 0.01) and stimulated (p < 0.05) 
melanocytes. The IRF1 expression was decreased (p < 0.001) and the IFITM1 
expression increased (p < 0.05) in unstimulated melanocytes transfected with 
miR-155 when compared to the control transfection. IFITM1 and IRF1 were 
strongly induced by IFN-γ, and IFITM1 was further increased (p < 0.01) upon 
the overexpression of miR-155. No difference between miR-155- and control-
transfected cells was found for IRF1 when the cells were stimulated by IFN-γ 
(Figure 18D). 
In a similar experiment in keratinocytes, the overexpression of miR-155 
suppressed the expression of YWHAE (p < 0.05) in unstimulated cells (Figure 
18E). SOCS1 and IRF1 were downregulated by miR-155 both in unstimulated 
(p < 0.05 and p < 0.01, respectively) and stimulated (both with p < 0.05) 
keratinocytes. As with the effect in melanocytes, the expression of IFITM1 was 
elevated in unstimulated (p < 0.001) and IFN-γ-stimulated (p < 0.001) keratino-




Figure 18. The relative expression of the melanogenesis-associated targets of miR-155 
and interferon-inducible genes in (A-D) melanocytes and (E, F) keratinocytes. (A–D) 
Human primary melanocytes and (E, F) keratinocytes were transfected either with a 
control (cont) or hsa-miR-155-5p mimic for 24 h and then stimulated with the interferon 
(IFN)-γ for 48 h or left unstimulated (us). The relative expression compared with 
unstimulated control-transfected cells (=1) is shown. The data represent the mean ± the 




9.1. Inflammatory changes are modest and  
suggest the involvement of type I interferons  
in the pathogenesis of vitiligo (Paper I) 
Although vitiligo is clinically a silent disease, at the cellular and molecular level 
moderate inflammatory changes still exist (Sandoval-Cruz et al, 2011). In 
accordance with multiple previous studies (Grimes et al, 2004; Moretti et al, 
2002; Regazzetti et al, 2015; Reimann et al, 2012; Singh et al, 2017), we 
predominantly detected only a moderate upregulation of some inflammatory 
cytokines (TNFA, IL36A, CCL5) in the marginal areas of the vitiligo lesions 
where the destructive processes occur (van den Boorn et al, 2009). Excep-
tionally, CXCL10, an IFN-inducible chemokine, was very strongly upregulated 
while IFNG remained undetectable. The importance of CXCL10 together with 
the closely related CXCL9 (Strassner et al, 2017) in the pathogenesis of vitiligo 
has been demonstrated by previous studies in humans as well as in mouse 
models (Rashighi et al, 2014; Regazzetti et al, 2015; Richmond et al, 2017; 
Wang et al, 2016c). Although CXCL10 is mainly known as an IFN-γ-induced 
and Th1-associated chemokine (Rashighi et al, 2014), the CXCL10 expression 
can also be influenced by type I IFNs (Moll et al, 2011). Indeed, recent evi-
dence suggests that type I IFNs play a role in vitiligo pathogenesis. Specifically, 
IFN-α producing plasmacytoid DCs infiltrate active vitiligo skin (Bertolotti et 
al, 2014; Jacquemin et al, 2017); pegylated IFN-α2a and IFN-α2b, which are 
used in the treatment of chronic hepatitis C, can induce depigmentation at the 
injection sites (Arya et al, 2010), and vitiligo patches have been observed at the 
site of the application of imiquimod, a Toll-like receptor (TLR)-7 and TLR-8 
agonist that enhances IFN-α production (Bertolotti et al, 2014; Li et al, 2014).  
In addition to CXCL10, in the current study the IFN-induced IFIH1 was 
upregulated in the vitiligo skin. IFIH1 is a gene which encodes an intracellular 
innate immune receptor called the melanoma differentiation-associated protein 
5 (MDA5) that binds double-stranded RNA (dsRNA). The expression of IFIH1 
has previously been observed to be induced by type I IFNs and to be implicated 
in autoimmune processes (Crampton et al, 2012). Moreover, IFIH1 is one of the 
risk genes for vitiligo (Jin et al, 2016). It is possible that during the course of 
vitiligo, type I IFNs are induced by the cyclic guanosine monophosphate  
(GMP) – adenosine monophosphate (AMP) synthase – cyclic GMP-AMP – the 
stimulator of the interferon genes (cGAS–cGAMP–STING) pathway after 
oxidative stress generated DNA damage (Hartlova et al, 2015; Jian et al, 2014). 
In this pathway, unrepaired DNA lesions induce type I IFNs via the cytosolic 
DNA sensor STING to promote the activation of innate immunity (Hartlova et 
al, 2015). To sum up, these results corroborate that inflammatory changes in the 
vitiligo skin are moderate and indirectly support the association between type I 
IFNs and vitiligo. Therefore, IFIH1 and CXCL10 as well as other components 
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of the type I IFN signalling pathway can be potential biomarkers or treatment 
targets for vitiligo. 
Among the studied cytokine receptors, only the IL22RA1 expression was 
increased in the non-lesional skin of the vitiligo patients. Whether this im-
plicates the IL-22 pathway in vitiligo pathogenesis remains unknown as the 
IL22 transcripts were below the detection limit. However, an upregulation of 
IL22 in the PBMCs of the vitiligo patients has been reported (Rätsep et al, 
2008). Additionally, in the vitiligo non-lesional skin, the inhibitory IL1RN 
(Aksentijevich et al, 2009) showed a slight increase. This change could repre-
sent compensatory responses that rebalance the signalling to limit inflammatory 
processes (Aksentijevich et al, 2009). However, this is unlikely as the plasma 
concentration of IL-1Ra, the protein encoded by the IL1RN gene, was lower in 
the patients with vitiligo, in comparison to the control individuals.  
In the plasma taken from the patients with vitiligo, we did not detect an 
increased concentration of any measured cytokines. Based on the findings of the 
skin gene expression analysis, these results are not unexpected. Interestingly, 
the concentration of G-CSF was significantly lower in the plasma of the vitiligo 
patients than in the control individuals. As G-CSF may have a pro-inflam-
matory or pro-repair influence depending on the context (Hamilton et al, 2017), 
the impact of this change is difficult to judge. To sum up, these results further 




9.2. Lymphoid stress surveillance response contributes to 
the pathogenesis of vitiligo (Paper I) 
The data reported here support the link between the lymphoid stress surveil-
lance response and vitiligo. In lymphoid stress surveillance, lymphocytes are 
rapidly activated through their non-clonotypic receptors and unleash their 
effector mechanisms, like cytokine secretion and cytotoxic mediators, without 
any delays (Shafi et al, 2011; Strid et al, 2011). This response is mediated by an 
interaction between stress molecules and different stress molecule binding 
receptors (Shafi et al, 2011). Tissue dysregulation can be sensed by lympho-
cytes via the recognition of stress molecules (like MICA/MICB) that have been 
upregulated by damaging agents like oxidative stress (Ghadially et al, 2017; 
Shafi et al, 2011). Although the MICA/MICB mRNA only showed a tendency 
for an increased expression in the vitiligo lesions, we could clearly observe 
staining for the MICA/MICB protein in the dermal area of the vitiligo lesional 
skin but not in the healthy or non-lesional skin. The much more dramatic diffe-
rences in the MICA/MICB protein expression in comparison to the mRNA 
expression can be explained by the posttranscriptional and posttranslational 
regulation of stress molecules (Ghadially et al, 2017). MICA/MICB are ligands 
for the activating NKG2D receptor encoded by the KLRK1 gene and expressed 
by NK cells, γδ T cells and a subpopulation of cytotoxic αβ T cells that are a 
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part of tissue-resident immune cells in the skin (Cheuk et al, 2017; Strid et al, 
2011). 
Previously, the involvement of innate cells in the vitiligo pathogenesis has 
been suggested (Yu et al, 2012). We could not detect a significant upregulation 
of TRGC1 that encodes a T cell receptor γ-chain (Hayday, 2019) arguing 
against the specific recruitment of γδ T cells to the vitiligo lesions. As this is a 
tissue resident population of innate-like T cells that is already located and ready 
to respond to stress signals by neighboring cells (Hayday, 2019), the lack of an 
increase in their number does not mean that they are not responding to the 
stress-ligands. However, as CTLA4 is expressed in Tregs as well as in the 
activated T cells and FOXP3, a marker of Tregs, was not upregulated in the 
vitiligo skin, we suggest that CTLA4 is upregulated in our samples due to the 
increased activation of the T cells in the skin of the vitiligo patients. Moreover, 
EOMES, a transcription factor characteristic of effector cytotoxic T cells, 
unconventional memory CD8+ T cells and NK cells (Collins et al, 2017; Jaco-
met et al, 2015; Martinet et al, 2015; White et al, 2016), was upregulated in 
both the vitiligo lesional and non-lesional skin. Unconventional memory CD8+ 
T cells is a heterogeneous subpopulation of the cells that acquire a memory 
phenotype in the absence of antigen exposure and once developed, they can 
respond immediately and vigorously to danger signals by releasing cytokines 
and cytotoxic mediators (Martinet et al, 2015; White et al, 2016). Innate and 
innate-like memory CD8+ cells as well as virtual memory T cells constitute the 
group of unconventional memory CD8+ T cells. The increase in the transcrip-
tion factor EOMES is consistent with the involvement of unconventional 
memory cytotoxic cells that similarly to innate cells respond readily to cyto-
kines and stress signals, and can be recruited by CXCL10 (Barbarin et al, 2017; 
Martinet et al, 2015). However, the precise cell type responsible for the 
lymphoid stress surveillance in vitiligo is yet to be identified. 
 
 
9.3. Autophagy is activated in vitiligo (Paper I) 
According to several hypotheses of vitiligo pathogenesis, melanocytes are not 
merely innocent bystanders that are attacked by cytotoxic cells but rather trigger 
the processes themselves by impaired oxidative stress responses and/or by dys-
regulated autophagic processes (Xie et al, 2016). Moreover, it has previously 
been shown that autophagy deficiency causes premature senescence and a 
decreased proliferation of melanocytes (Zhang et al, 2015), and melanosomal 
autophagy in stressed melanocytes mediates antigen presentation and DC 
maturation (Xie et al, 2016). 
We demonstrated the highly significant downregulation of WIPI1 in the 
lesional and non-lesional skin of the vitiligo patients. WIPI1 is a gene that 
regulates autophagy as well as melanosome maturation (Akinduro et al, 2016; 
Ho et al, 2011). As the studied cell cultures revealed that WIPI1 was most 
strongly expressed in melanocytes, then WIPI1 downregulation in the vitiligo 
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skin could be the result of melanocyte loss in the lesions. Nevertheless, this is 
unlikely regarding the reduced WIPI1 expression also in the vitiligo non-
lesional skin. However, melanosomes are also lysosome-related organelles 
whose formation is regulated by molecules overlapping with autophagy 
regulators like WIPI1 and LC3 (Ho et al, 2011; Yun et al, 2016). Therefore, in 
the vitiligo skin, WIPI1 downregulation could be linked with an impaired 
formation of melanosomes rather than with dysregulated autophagy. 
According to our results, the downregulation of WIPI1 in the vitiligo skin 
and the activation of autophagy are uncoupled processes as the WIPI1 expres-
sion was reduced to a similar degree in the lesional and non-lesional skin 
whereas LC3 staining clearly indicated an increased autophagy only in the 
keratinocytes of the lesional skin. Whether the activated autophagy in the 
vitiligo keratinocytes represents a compensatory mechanism for the lack of 
melanin, is responsible for the faster degradation of the remaining melanin pro-
duced by residual melanocytes in the vitiligo skin (Tobin et al, 2000) or is the 
result of an increased stress-surveillance response in the skin remain un-
answered at present. Autophagy and nucleophagy are suggested to be essential 
for normal epidermal development and differentiation (Akinduro et al, 2016). 
To the best of our knowledge, this is the first demonstration of excessive 
autophagy in the vitiligo keratinocytes. However, alterations in keratinocytes 
have been found by previous transcriptional studies (Singh et al, 2017). This 
suggests that the cross-talk between different skin cell types is relevant in the 
pathogenesis of vitiligo. Collectively, our results support the hypothesis that 
autophagy is activated in the vitiligo lesions involving melanocytes as well as 
keratinocytes. This evidence calls for further research into autophagy as a 
candidate treatment target for vitiligo. 
 
 
9.4. A model to explain  
the pathogenesis of vitiligo (Paper I) 
Based on the results of this study, we propose a model wherein different stres-
sors like UV irradiation or altered melanosome maturation lead to an increased 
oxidative stress that can cause DNA damage (Figure 19). Damaged cells 
upregulate stress-ligands and the production of type I IFNs that in turn induce 
CXCL10 secretion from keratinocytes, which then attracts CXCR3 positive T 
cells. Stress-ligands can be bound by activating receptors on innate and innate-
like T cells which deploy their effector mechanisms and cause the release of 
autoantigens from dying cells. This can prime the responses of antigen-specific 
T and B cells, which participate in the perpetuation of tissue damage. These 
findings reveal some informative traces that would help dissect the processes 




Figure 19. Model for the pathogenesis of vitiligo. Different external stressors like ultra-
violet (UV) light or internal stressors like altered melanosome maturation (1) induce 
oxidative stress that damages DNA (2). Damaged cells upregulate stress-ligands, such 
as a MHC class I polypeptide-related sequence A (MICA)/MICB (3), and induce the 
production of type I interferons (IFNs) through the activation of the stimulator of 
interferon genes (STING)-pathway (4). Type I IFNs in turn induce C-X-C motif 
chemokine ligand 10 (CXCL10) secretion from keratinocytes (5, 6), which then attract 
chemokine receptor CXCR3 positive T cells (7). Stress-ligands can be bound by 
activating receptors on unconventional memory CD8+ T cells and NK cells that deploy 
their effector mechanisms (8) and cause the release of autoantigens from dying cells. 
This can prime the responses of antigen-specific T and B cells (9), which participate in 




































9.5. Local and systemic inflammation is severe in psoriasis 
(Paper II) 
Psoriasis is a prototypical Th17 pathway-mediated chronic inflammatory di-
sease (Swindell et al, 2016; Xing et al, 2016) and biologicals blocking this 
pathway have shown high efficacy in the treatment of psoriasis (Blauvelt et al, 
2017; Canavan et al, 2016; Lowes et al, 2014). The findings of this study 
confirm the central role of Th17 cytokines in psoriasis. In accordance with the 
upregulation of Th17 cytokines (IL17A, IL17F, IL22, IL26), the chemokines 
induced by IL-17A from keratinocytes (CXCL1, CXCL2, CXCL8) (Chiricozzi et 
al, 2011) were upregulated in the psoriatic skin. Additionally, other proinflam-
matory cytokines (IFNG, TNFA, IL1B, IL36A) and chemokines (CCL2, CCL5 
and CCL20) that recruit various inflammatory cells, including monocytes, DCs 
and Th17 cells (Ogawa et al, 2018), were highly expressed. Th17 cytokines are 
potent inducers of antimicrobial peptides, such as S100A8, S100A9, PI3 and 
LCN2 (Liang et al, 2006; Shao et al, 2016), all of which were upregulated in our 
study. 
CCL27 was the only chemokine downregulated in the psoriatic skin. It is a 
skin specific chemokine that recruits CCR10+ lymphocytes to maintain skin 
homeostasis (Fu et al, 2016; Yang et al, 2016). In epithelial cell culture, CCL27 
is upregulated by IL-17 (Karakawa et al, 2014) and previous studies have con-
vincingly shown its decrease in psoriatic lesions (Gudjonsson et al, 2010; 
Quaranta et al, 2014) and suggested this as a useful biomarker for the differen-
tiation of psoriasis from atopic dermatitis in complicated differential diagnostic 
cases (Quaranta et al, 2014). The downregulation of CCL27 in psoriatic skin 
would decrease the influx of immune cells that could counterbalance inflam-
mation in the skin. Indeed, the expression of negative regulators of immune 
responses, specifically the Tregs marker FOXP3, coinhibitory molecules 
CTLA4, IL10 and IL1RN, were markedly increased in the psoriatic lesions and 
IL-1Ra, the protein encoded by IL1RN, was elevated in the plasma of the 
psoriatic patients. However, FOXP3+ Tregs can lose their regulatory capacity in 
the inflammatory environment and start producing IL-17A which has been 
reported to happen in psoriatic skin (Bovenschen et al, 2011). In conclusion, 
these data are in line with multiple previous studies confirming the central role 
of Th17 cytokines in psoriasis (Boehncke & Schon, 2015). 
Psoriasis is not a skin-restricted disease but in severe forms manifest many 
systemic features that in our study are exemplified by increased levels of 
several inflammatory mediators (CXCL8, IL-17A, IL-6, TNF-α) in the circu-
lation. From the mediators with elevated serum levels, IL-17A was associated 
with the severity of the disease. This result confirms previous findings by 
Takahashi et al. (Takahashi et al., 2010). The IL-6 level was higher in the 
patients with psoriatic arthritis in our samples. Elevated levels of IL-6 in the 
serum and synovial fluid of patients with psoriatic arthritis have previously 
been reported and the efficiency of IL-6-targeted therapy in the treatment of 
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psoriatic arthritis is being studied (Mease et al, 2016). This supports the theory 
that IL-6 is a marker for psoriasis arthritis. 
 
 
9.6. Autoinflammatory mechanisms are activated in the 
skin of the psoriasis patients (Paper II) 
There is still no consensus about whether psoriasis is an autoimmune disease 
driven by autoantigen-specific T cells or an autoinflammatory disease provoked 
primarily by innate receptor signalling and innate-type cell activation in 
response to stress signals (Havnaer & Han, 2019). To clarify the importance of 
autoinflammatory mechanisms provoked primarily by innate receptor signalling 
in response to stress signals in psoriasis, we studied inflammasome components, 
several innate receptors and components of the autophagosome in the skin of 
the psoriasis patients. 
Previous studies have revealed that mTOR signalling, which is known also 
as a negative regulator of autophagy, is hyperactivated in a psoriatic epidermis 
(Buerger et al, 2017) and the expression of LC3 as well as WIPI1 is reduced in 
a psoriatic epidermis (Akinduro et al, 2016). Contrary to our expectations, we 
did not find differences in the expression level of WIPI1 in the psoriasis pa-
tients compared to the control individuals. The possible explanation for this 
discrepancy might be related with the differences in the study participants or the 
methods used. Further research is needed to explain the role of impaired 
autophagy in psoriasis. 
However, our results support recent discoveries that several innate receptors 
are involved in the pathogenesis of psoriasis (Tervaniemi et al, 2016). IFIH1, 
which encodes a receptor recognising dsRNA, showed elevated expression 
levels in the psoriatic lesions. It has previously been shown that the antimicro-
bial peptide LL37 induces the production of IFN-β by keratinocytes in response 
to dsRNA that is released from dying cells (Lande et al, 2015; Zhang et al, 
2016). In our study, the upregulation of IFN-induced chemokine CXCL10 in the 
psoriatic skin may indicate an enhanced IFN-signalling in psoriasis. Moreover, 
the therapeutic removal of the type I IFN receptor IFNAR by UV therapy has 
proven to be effective in the inflammation treatment of psoriatic skin (Gui et al, 
2016). Additionally, AIM2, an innate receptor binding to dsDNA, was ex-
pressed at increased levels in the psoriatic skin in our study, being consistent 
with previous reports (de Koning et al, 2012; Dombrowski et al, 2011; Terva-
niemi et al, 2016). 
AIM2 is a component of inflammasomes and when activated, it recruits the 
adaptor protein ASC, which is encoded by the PYCARD gene to form in-
flammasomes and activate caspase-1, which cleaves pro-IL-1β to its bioactive 
form and induces pyroptosis (Man et al, 2016). Indeed, we showed the elevated 
expression of both genes – PYCARD and IL1B – in the psoriatic lesions. 
Previously, an increased level of active caspase-1 has been revealed in the 
lesional psoriatic epidermis via western blot (Dombrowski et al, 2011; Johansen 
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et al, 2007). Using the fluorescent detection of active caspase-1, we found 
caspase-1 in the granular layer of the normal healthy epidermis but not in the 
dermis, which indicates its physiological role in epidermal maturation. Psoriatic 
lesions revealed increased levels of active caspase-1 in the whole epidermis as 
well as in the subepidermal areas. Our data also confirm the recent finding that 
NLRP1 and NLRP3 inflammasomes are not differentially expressed in psoriasis 
(Tervaniemi et al, 2016), although single nucleotide polymorphisms in NLRP3 
are associated with wide-spread psoriasis (Carlström et al, 2012). 
The source of the activating signal for AIM2 still remains to be identified. 
One possibility is that keratinocytes are the sources of the activating signal, as 
keratinocytes in psoriatic skin display free cytoplasmic dsDNA (Dombrowski et 
al, 2011). Another possibility is that the activating signal derives from neutro-
phils. Using immunofluorescence, de Koning et al. have demonstrated that there 
is AIM2 staining adjacent to Munro’s microabscesses, which are the collections 
of neutrophils in stratum corneum of the psoriatic lesions (de Koning et al, 
2012). Regarding the capability of neutrophils to undergo extracellular trap 
formation (NETosis) that releases huge amounts of immunostimulatory dsDNA, 
the location of AIM2 is perfect for responding to this signal. However, at this 
stage we can only speculate about the inflammasome type involved and the 
cause for its activation. Nevertheless, finding the involvement of inflamma-
somes and innate receptors in psoriasis strongly suggests the increased activa-
tion of innate immunity in psoriatic lesions and paves the way for the develop-
ment of new effective treatment options for this serious inflammatory disease. 
 
 
9.7. Innate and innate-like cells participate in the 
development of psoriasis (Paper II) 
Multiple effector cells can mediate inflammation in psoriasis, such as cytotoxic 
T cells, NK cells, γδ T cells and neutrophils (Cai et al, 2013; Lowes et al, 2014). 
The most abundant effector cells in psoriatic skin are lymphocytes, out of which 
CD4+ cells mostly locate in the dermis and CD8+ cells in the epidermis (Cheuk 
et al., 2014; Di Meglio et al., 2016). Whereas the T cell response in psoriatic 
skin is highly polyclonal, it is unlikely that a single or a couple of autoantigens 
induce the disease (Harden et al, 2015a). To get information about innate cell 
infiltration to the skin of the psoriasis patients, we measured the expression of a 
stress molecule and several stress molecule binding receptors. 
Our study is the first to describe an elevated level of EOMES in the psoriatic 
lesions and in the non-lesional skin at mRNA as well as protein levels, locating 
especially in the nuclei of the CD3+ T cells. As mentioned before, EOMES is 
an important transcription factor for CD8+ T cell development and effector 
function exertion (Knox et al, 2014; McLane et al, 2013). Moreover, EOMES is 
critical for the development of unconventional memory CD8+ T cells, which 
are T cells that activate rapidly without TCR stimulation, are IL-15 dependent 
and have innate-like functions, such as the capability to rapidly produce 
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inflammatory cytokines in the absence of antigenic recognition (Jacomet et al, 
2015; Martinet et al, 2015; White et al, 2016). Recently, Collins et al. showed 
that EOMES is an essential factor for the development of NK cells as well 
(Collins et al, 2017). We did not see any statistically significant difference in 
the NK cell-specific gene KLRK1 expression but interestingly, we found a 
moderate increase in the stress molecule MICB expression in the psoriatic skin 
which makes the cells vulnerable to the attack of NK cells, γδ T cell and tissue-
resident cytotoxic αβ T cells (Cheuk et al, 2014; Hayday, 2009; Knight et al, 
2012; Strid et al, 2011). Moreover, although the first suspects for making IL-
17A in the psoriatic lesional skin were Th17 cells, several recent studies have 
pointed to CD8+ and γδ T cells as an important IL-17A source in this disease 
(Cai et al, 2013; Di Meglio et al, 2016; Hijnen et al, 2013; Kim et al, 2016; 
Laggner et al, 2011). While we were unable to see any significant differences in 
the T cell receptor gamma chain TRGC1 expression in the psoriatic skin, we 
cannot rule out an increase in the proportion of IL-17A secreting cells. Indeed, 
Harden et al. detected several γ-chain sequences that were shared by the 
psoriasis patients’ skin samples (Harden et al, 2015a).  
The evidence of this study suggests the involvement of innate-type lympho-
cytes in the pathogenesis of psoriasis, but the precise role of T cells in psoriasis 
needs further clarification, including the possible role of unconventional cells, 
their potential therapeutic modification (e.g. by blocking IL-15) and their 
relation to tissue-resident memory cells (Cheuk et al, 2017; Watanabe et al, 
2015). In conclusion, our data are in line with studies that support the auto-
inflammatory pathogenesis of psoriasis which involves multiple innate recep-
tors and innate cell types, probably including the recently described unconven-
tional memory cytotoxic cells. It is therefore possible that also lymphoid stress 
surveillance response participates in the pathogenesis of psoriasis. 
 
 
9.8. MiRNAs participate in the pathogenesis of vitiligo 
(Paper III) 
One purpose of this thesis was to assess the expression changes and role of 
miRNAs in vitiligo pathogenesis. The current study found that miR-99b, miR-
155, miR-199a-3p, miR-125b and miR-145 are dysregulated in the skin of the 
patients with vitiligo. Moreover, several putative targets associated with 
melanocyte differentiation and melanogenesis were predicted by pathway 
analysis for miR-99b, miR-125b, miR-155 and miR-199a-3p, and were proved 
experimentally for miR-155. 
Previously, miRNA expression profiles in the PBMCs (Wang et al, 2015b), 
serum (Shi et al, 2013), whole blood (Shang & Li, 2017) and skin (Mansuri et 
al, 2014; Sahoo et al, 2017) of vitiligo patients have been investigated. We 
confirm Mansuri’s finding (Mansuri et al, 2014) that the expression of miR-99b 
is increased in the skin of vitiligo patients. The finding that miR-125b, miR-155 
and miR-199a-3p are dysregulated in the skin of vitiligo patients has previously 
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not been reported. Although the downregulation of miR-10a and the upregu-
lation of miR-223 have earlier been observed in the serum of vitiligo patients 
(Shi et al, 2013), we did not detect any differences in the expression levels 
between the skin of the control subjects and the patients with vitiligo. This 
indicates that there could be differences in the expression levels of miRNAs in 
the skin and serum. Additionally, Mansuri et al. reported an upregulation of 
miR-145 in the vitiligo skin (Mansuri et al, 2014). In our study, miR-145 was 
downregulated in the vitiligo lesions. This discrepancy might be due to varia-
tion in study participants’ characteristics or the technical approach, including 
differences in ethnicity, RNA extraction methods and miRNA expression 
evaluation methods. However, these results suggest that miRNAs are involved 
in the pathogenesis of vitiligo.  
 
 
9.9. miR-155 contributes to the pathogenesis of vitiligo, 
modulating melanogenesis-associated and interferon-
inducible genes in melanocytes and keratinocytes  
(Paper III) 
Among dysregulated miRNAs, we found an increased expression of miR-155 in 
the epidermis of the vitiligo lesional skin, on the site where keratinocytes and 
melanocytes are located. In contrast, previous studies have demonstrated the 
expression of miR-155 mainly in immune cells (Dudda et al, 2013; Sonkoly et 
al, 2010). To understand whether proinflammatory vitiligo-associated cytokines 
can affect the expression of miR-155 in skin cells, we stimulated human 
primary melanocytes and keratinocytes with TNF-α, IFN-α, IFN-γ and IL-1β. 
From these cytokines, TNF-α, IFN-γ and IL-1β are dysregulated in the lesional 
skin, serum, PBMCs and the whole blood of vitiligo patients and these 
cytokines are known to inhibit melanocyte proliferation and melanogenesis 
(Camara-Lemarroy & Salas-Alanis, 2013; Laddha et al, 2014; Reimann et al, 
2012; Tu et al, 2003). In addition, several indications that IFN-α plays a role in 
the pathogenesis of vitiligo (Arya et al, 2010; Bertolotti et al, 2014; Jacquemin 
et al, 2017; Li et al, 2014) are listed above (paragraph 9.1.). Thus, any miRNA 
modulating the pathways associated with the production or effect of these 
cytokines potentially influences the development of vitiligo. Indeed, miR-155 
was induced in response to the vitiligo-associated cytokines in melanocytes as 
well as keratinocytes. It can thus be suggested that the presence of inflam-
matory cytokines in the skin of the patients with vitiligo modulates inflam-
matory responses and activates the expression of miR-155 in melanocytes and 
keratinocytes. 
miR-155 is known as a proinflammatory miRNA, which among other targets 
suppresses SOCS1. This results in the activation of the Janus kinase-signal 
transducer and the activator of the transcription (JAK-STAT) pathway and, 
consequently, in type I and II IFN signalling (Wang et al, 2010). We found that 
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when overexpressed, miR-155 inhibited the expression of genes known to affect 
melanocyte differentiation and melanogenesis, such as TYRP1, YWHAE, 
SDCBP and SOX10 in melanocytes, and YWHAE in keratinocytes. Additionally, 
the miR-155 overexpression altered the levels of interferon-regulated genes 
SOCS1, IRF1 and IFITM1 in melanocytes and keratinocytes. It is possible that 
miR-155 contributes to the pathogenesis of vitiligo, both through the targeting 
of melanogenesis-associated genes and via the modulation of IFN signalling. 
Multiple functions of miR-155 in vitiligo pathogenesis is supported by Lv et al 
who found that miR-155 is downregulated in the T cells isolated from the 
PBMCs of vitiligo patients and that the overexpression of miR-155 promoted 
the differentiation and function of Treg cells (Lv et al, 2019). 
In addition to miR-155, other dysregulated miRNAs might contribute to the 
development of vitiligo. For example, miR-125b is downregulated after the 
induction of pigmentation in melanocytes (Dynoodt et al, 2013) and miR-125b 
mimics have been demonstrated to inhibit the expression of pigmentation-
related genes (Kim et al, 2014). Similarly to miR-125b, the expression of miR-
145 has been demonstrated to be decreased in cultured pigment cells after the 
induction of pigmentation (Dynoodt et al, 2013). The pathway analysis in our 
study detected possible direct targets for miR-145 among the MAPK, JNK and 
TGF-β pathways, which can disturb the viability and functionality of melano-
cytes (Bellei et al, 2013). Although no significant overlap was revealed between 
the miR-145 targets and genes associated with pigmentation, a computer 
analysis with Targetscan suggested the presence of binding sites for miR-145 in 
the mRNAs of melanogenesis-associated genes RAB27A, SOX9 and FCSN1 
(data not shown). This is in line with the previous findings demonstrating the 
influence of miR-145 on genes involved in the pigmentation in miR-145-
transfected cells (Dynoodt et al, 2013). 
To summarise, we demonstrated that miR-99b, miR-125b, miR-145, miR-
155 and miR-199a-3p are dysregulated in the skin of the patients with vitiligo, 
and showed that miR-155 has the capacity to modulate melanogenesis-as-
sociated and interferon-inducible genes in melanocytes and keratinocytes. The 
dysregulated miRNAs could be used as predictive markers in the diagnosis and 
treatment of vitiligo. 
 
 
9.10. Concluding remarks and future prospects 
The results of this study support several previous findings and provide much 
new information about the pathogenesis of vitiligo and psoriasis, but many 
questions still remain to be answered and need further investigation. First, the 
current data highlight the importance of innate immunological mechanisms in 
the development of both chronic dermatoses – vitiligo and psoriasis. Further 
studies need to be carried out in order to specify the role of innate immunity 
components in these diseases and to clarify the value of the components as 
possible therapeutic, diagnostic or prognostic targets. Special attention needs to 
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be paid to eomesodermin positive skin infiltrating cells in vitiligo as well as 
psoriasis. Second, the specific and/or overlapping roles of type I and II IFNs in 
vitiligo are yet to be substantiated. Third, considering the alteration of auto-
phagy in the epidermis of the vitiligo patients, another aspect that needs to be 
elucidated is the pathogenic role of autophagy in developing vitiligo. Whether 
the activated autophagy in vitiligo keratinocytes represents a compensatory 
mechanism for the lack of melanin, is responsible for the faster degradation of 
the remaining melanin produced by residual melanocytes in the vitiligo skin or 
is the result of an increased stress-surveillance response in the skin, needs to be 
studied. Furthermore, studies are needed to clarify whether miR-155 and other 
dysregulated miRNAs described in this study are suitable diagnostic markers 
and/or targets for the treatment of vitiligo. Finally, considering the upregulation 
of EOMES, CXCL10, IFIH1 and MICB in the skin of the patients with vitiligo 
as well as psoriasis, we can propose that there are some overlapping mecha-
nisms between these diseases that need to be uncovered in the future. 
It needs to be acknowledged that our work has some limitations, which must 
be recognised for a more balanced interpretation of the results. Firstly, the 
number of participants in the study was relatively low, which could skew the 
data and give a distorted view of the results. Secondly, there were only few 
novel findings in our study as a substantial part of our gene expression analysis 
confirmed previously published results. On the other hand, the reproducibility 
of the previous findings strengthens their reliability. Despite these limitations, 
we believe that the results are still valuable for a better understanding of the 




1. We observed that a strong local and systemic inflammation is associated 
with psoriasis but not with vitiligo. While psoriasis is a Th17-mediated 
disease, indirect evidence suggests the involvement of type I IFNs in the 
disease process of vitiligo. 
2. The gene expression and immunofluorescence analysis of skin biopsy 
samples identified several innate-like lymphocyte subpopulations and 
receptors in the lesions of psoriasis and vitiligo. These results support the 
role of the lymphoid stress surveillance response in vitiligo and psoriasis 
pathogenesis. 
3. Inflammasomes were activated in the epidermis as well as the dermis in the 
psoriatic skin but the involvement of inflammasomes in vitiligo pathogenesis 
was not supported by this study. In contrast, autophagy was activated in the 
vitiligo lesions, involving melanocytes and keratinocytes. 
4. Several miRNAs were dysregulated in the skin of the vitiligo patients and 
had various melanocyte-associated putative targets. From dysregulated 
miRNAs, the functional studies on miR-155 revealed its capacity to impact 
genes associated with melanogenesis and inflammatory responses in melano-
cytes and keratinocytes. These data suggest that miR-155 may contribute to 
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12. SUMMARY IN ESTONIAN 
Molekulaarsed muutused kahe kroonilise dermatoosi –  
vitiliigo ja psoriaasi – patogeneesis 
 
Üldteoreetiline taust 
Vitiliigo on sagedaseim pigmendikaona väljenduv krooniline nahahaigus. Kuna 
vitiliigo avaldub tihti lapse- või noorukieas, lokaliseerub enamasti avatud keha-
piirkondadesse ja puuduvad head ravivõimalused, mõjutab see oluliselt pat-
siendi elukvaliteeti. Pigmendi kadu on tingitud melanotsüütide hävinemisest, 
kuid senini on ebaselge, mis melanotsüütide vastase reaktsiooni vallandab ja 
kuidas seda reaktsiooni alal hoitakse. 
Psoriaas on sage kompleksse patogeneesiga põletikuline nahahaigus, mis 
väljendub punetavate ja ketendavate naastudena nahal. Psoriaasi korral esineva 
põletiku süsteemset iseloomu toetab ~50%-l haigetest kaasnev küünekahjustus, 
~30%-l kaasnev liigeshaaratus ja tavapopulatsioonist sagedamini esinevad kroo-
nilised haigused, nagu kardiovaskulaarsed haigused, diabeet jt. Arengud pso-
riaasi ravis võimaldavad kasutada efektiivseid bioloogilisi preparaate, mis 
blokeerivad põletikulisi tsütokiine – tuumorinekroosifaktor (TNF)-α, inter-
leukiin (IL)-23, IL-17. Senini ei ole aga täpselt teada, kas psoriaasi korral esi-
neva põletiku tekkes omavad olulisemat rolli autoimmuunsed mehhanismid, 
mis on vahendatud autoantigeeni spetsiifiliste T-rakkude poolt, või pigem auto-





Antud doktoritöö eesmärgiks oli hankida uut informatsiooni kahe dermatoosi – 
vitiliigo ja psoriaasi – patogeneesi kohta. Täpsemaks eesmärgiks oli uurida viti-
liigo ja psoriaasi korral esinevat paikset ja süsteemset põletikulist vastust, saada 
informatsiooni nende haiguste korral nahka infiltreerivate immuunrakkude 
kohta, täpsustada inflammasoomide ja autofaagia kaasatust vitiliigo ja psoriaasi 
patogeneesis ning kirjeldada mikroRNA(miRNA)de ekspressioonimuutusi ja 
tähtsust vitiliigo tekkes. 
 
 
Uuritavate grupid ja metoodika 
Uuringusse kaasasime kokku 23 mittesegmentaalse vitiliigoga patsienti, 43 
naastulise psoriaasiga patsienti ja 32 kontrollindiviidi. Uuritavate nahast määra-
sime põletikulisi tsütokiine, retseptoreid, immuunrakkude markereid ja nende 
ligande ning inflammasoomi ja autofaagia komponente kodeerivate infor-
matsiooniRNAde (messengerRNA, mRNA) suhtelist ekspressiooni. Selleks 
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kasutasime kvantitatiivse reaalaja polümeraasi ahelreaktsiooni (qRT-PCR) 
meetodit. Plasmast mõõtsime põletikuliste tsütokiinide kontsentratsiooni Lu-
minex meetodiga. Immunofluorestsentsuuringuga hindasime vitiliigohaigete 
nahas raku stressi ja autofaagia markeri avaldumist ning psoriaasihaigete nahas 
tsütotoksiliste lümfotsüütide transkriptsioonimarkeri eomesodermiini avaldu-
mist. Psoriaasihaigete nahas hindasime inflammasoomi põhikomponendi 
kaspaas-1 aktiivsust. 
Lisaks määrasime vitiliigohaigete nahas miRNAde suhtelist ekspressiooni 
qRT-PCRiga. miR-155 lokalisatsiooni nahas hindasime in situ hübridisatsioo-
niga. Potentsiaalsete miRNA märklaudgeenide tuvastamine toimus Target-
Scan’i abil ja signaalradade otsimiseks kasutasime g:Profiler’it. 
Veel kasutasime erinevaid rakupopulatsioone – melanotsüüte, keratinot-
süüte, fibroblaste ja Langerhansi rakke. Rakupopulatsioonides määrasime 
autofaagia markeri ja miRNAde avaldumist qRT-PCRiga. Melanotsüütidel ja 
keratinotsüütidel viisime läbi stimulatsioonikatse, milles hindasime põletikuliste 
tsütokiinide mõju miR-155 avaldumisele. Hindamaks miR-155 efekti melano-
geneesiga seotud ja interferoonide poolt indutseeritavatele geenidele, teostasime 
melanotsüütide ja keratinotsüütide transfektsiooni miR-155-ga misjärel mõõtsi-
me mRNAde ekspressiooni. 
 
 
Tulemused ja arutelu 
Leidsime, et vitiliigot põdevate patsientide nahas olid uuritud tsütokiinidest ja 
kemokiinidest kõrgelt ekspresseerunud TNFA, IL36A e IL1F6, CCL5 ja 
CXCL10. Kuigi interferoon (IFN)-γ kodeeriv IFNG ei olnud uuritavate nahas 
määratav, oli vitiliigohaigete nahas kõrgelt avaldunud loomuliku immuun-
süsteemi töös osalev retseptor IFIH1 ja kemokiin CXCL10, mis mõlemad on 
teadaolevalt valdavalt IFN-γ poolt indutseeritavad. Kuna aga varasemast on 
teada, et CXCL10 ekspressiooni võivad mõjutada peale IFN-γ ka I tüüpi inter-
feroonid (IFN-α ja IFN-β) ning on mitmeid kaudseid viiteid I tüüpi inter-
feroonide osalemisele vitiliigo patogeneesis, on võimalik, et CXCL10 ja IFIH1 
ekspressiooni haigetel aktiveerivadki just I tüüpi interferoonid. Tsütokiinide 
määramine plasmast süsteemset põletikku vitiliigohaigetel ei toetanud – me ei 
täheldanud ühegi määratud tsütokiini kontsentratsiooni suurenemist vitiliigo-
haigetelt kogutud plasmas. Nahka infiltreerivate rakkude markeritest olid 
vitiliigot põdevate patsientide nahas kõrgelt avaldunud aktiveeritud T-rakkudel 
ja regulatoorsetel T-rakkudel ekspresseeruv CTLA4 ja tsütotoksiliste lümfo-
tsüütide transkriptsioonifaktor EOMES. Täpsemalt on EOMES e eomesoder-
miin tsütotoksliste efektor-T-lümfotsüütide, NK-rakkude ja sünnipäraste oma-
dustega tsütotoksiliste T-lümfotsüütide transkriptsioonifaktor. NK-rakud ja 
sünnipäraste omadustega T-lümfotsüüdid ei vaja aktivatsiooniks T-raku retsep-
tori (TCR) stimulatsiooni ja nendel rakkudel on valmisolek kiiresti reageerida 
ohusignaalidele. Kuna immunofluorestsentsuuringuga leidsime, et raku stressi 
korral avalduv ligand MICA/MICB on vitiliigo haiguskoldes subepidermaalselt 
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paiknevates deformeerunud rakkudes avaldunud, võime oletada, et stressligand 
aktiveerib sünnipäraste omadustega tsütotoksilisi T-rakke. Autofaagia ja 
melanosoomide küpsemise regulaator WIPI1 oli nii vitiliigo haiguskoldes kui 
ka vitiliigo näiliselt terves nahas allareguleeritud. Selgitamaks välja, kas viti-
liigo korral on WIPI1 regulatsioonihäire tingitud pigem autofaagia häirumisest 
või melanosoomide küpsemise häirumisest, määrasime immunofluorestsent-
uuringu abil autofaagia markeri LC3 avaldumismustrit nahas. Vitiliigo haigus-
koldes nii üksikutes jäänukmelanotsüütides kui ka keratinotsüütides kogu epi-
dermise ulatuses oli LC3 võtnud kuju, mis on iseloomulik aktiveerunud auto-
faagiale. 
Psoriaasi uuringu tulemused on kooskõlas paljude teiste töödega, mis toe-
tavad nii lokaalse kui ka süsteemse põletiku esinemist psoriaasiga patsientidel. 
Leidsime, et psoriaasi põdevate patsientide nahas on kõrgelt avaldunud Th17-
lümfotsüütide toodetavad tsütokiinid (IL17A, IL17F, IL22, IL26), IL-17A 
toimel keratinotsüütidest vabanevad kemokiinid (CXCL1, CXCL2, CXCL8), 
mitmed teised põletikulised tsütokiinid (IFNG, TNFA, IL1B, IL36A) ja kemo-
kiinid (CCL2, CCL5, CCL20) ning Th17 tsütokiinide poolt indutseeritavad 
antimikroobsed peptiidid (S100A8, S100A9, PI3 ja LCN2). Ainult CCL27, 
kemokiin, mis kinnitudes CCR10 retseptoriga vahendab lümfotsüütide liikumist 
nahka, oli psoriaasihaigete nahas madalalt avaldunud. See viitab põletiku 
kontrollimehhanismide aktiveerumisele, millele antud uuringus osutas ka põle-
tiku negatiivsete regulaatorite (FOXP3, IL10, CTLA4, IL1RN) kõrge avaldu-
mine psoriaasihaigete nahas. Põletikuliste tsütokiinide (CXCL8, IL-17A, IL-6, 
TNF-α) kõrge kontsentratsioon plasmas viitab süsteemsele põletikule. Lisaks 
leidsime toetust hüpoteesile, et psoriaasi tekkes on oluline osa häirunud loomu-
likul immuunsusel. Nimelt olid meie uuringus kõrgelt avaldunud mitmed sünni-
pärase immuunsuse töös osalevad molekulid – dsRNAga seonduv retseptor 
IFIH1, interferoonide poolt indutseeritav CXCL10, inflammasoomide kompo-
nendid AIM2, PYCARD, IL1B ning rakkude stressi korral avalduv ning NK-
rakkude ja nahas persisteeruvate T-rakkudega seonduv ligand MICB. Inflamma-
soomi komponentide mRNAde ülesregulatsioon ja kaspaas-1 aktivatsioon 
psoriaasihaigete nahas epidermises ja dermise ülaosas osutavad autoinflmma-
toorsete mehhanismide olulisusele psoriaasi patogeneesis. Leidsime, et tsüto-
toksiliste lümfotsüütide transkriptsioonimarker EOMES on psoriaasihaigete 
nahas ülesreguleeritud nii mRNA kui ka valgu tasemel eomesodermiinina T-
lümfotsüütides. See võib olla põhjustatud loomuliku immuunsuse tsütotoksiliste 
rakkude aktivatsioonist. Autofaagia markeri WIPI1 avaldumishäiret me pso-
riaasihaigete nahas ei tuvastanud. 
MiRNAd on lühikesed mittekodeerivad nukleotiidide järjestused, mis seon-
dudes mRNAga inhibeerivad geenide ekspressiooni. Uuringusse valisime 
immunoloogilisi protsesse, melanogeneesi ning rakkude proliferatsiooni, dife-
rentseerumist ja apoptoosi reguleerivad miRNAd. Täpsustamaks mikroRNAde 
rolli vitiliigo patogeneesis, määrasime miRNAde (miR-10a, miR-99b, miR-
125a, miR-125b, miR-145, miR-146a, miR-146b, miR-155, miR-199a-3p, miR-
203, miR-223, miR-511) ekspressiooni vitiliigohaigete nahas. Leidsime, et 
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vitiliigohaigete nahas olid ülesreguleeritud miR-99b, miR-125b, miR-155 ja 
miR-199a-3p ning allareguleeritud miR-145. Ülesreguleeritud miRNAdele 
tuvastasime mitmeid melanogeneesiga seotud potentsiaalseid märklaudgeene. 
In situ hübridisatsiooni alusel oli miR-155 vitiliigohaigete epidermises tugevalt 
avaldunud. Stimulatsioonikatsete abil näitasime, et vitiliigo patogeneesis osale-
vad põletikulised tsütokiinid TNF-α, IFN-γ, IFN-α ja IL-1b aktiveerivad miR-
155 ekspressiooni nii melanotsüütides kui ka keratinotsüütides. Et veelgi täp-
sustada miR-155 kaasatust vitiliigo patogeneesis, teostasime melanotsüütide ja 
keratinotsüütide transfektsiooni hsa-miR155ga. Selle tulemusena leidsime, et 
miR-155 toimel muutub mitmete interferoonidega seotud ja melanogeneesis 
osalevate geenide avaldumine nii melanotsüütides kui ka keratinotsüütides. 
Meie uuring näitab, et miRNAd osalevad vitiliigo patogeneesis ja nende funkt-




Meie töö tulemused kinnitasid varasemaid uuringuid, et psoriaasi korral on 
põletik eeskätt Th17-vahendatud, samas näitasime loomulikus immuunsuses 
osalevate 1. tüüpi interferoonide rolli vitiliigo puhul. Saime toetust hüpoteesile, 
et loomuliku immuunsuse talitlusega seotud rakkude funktsioon on nii vitiliigo 
kui ka psoriaasi tekkes olulise tähendusega. Tuvastasime, et psoriaasihaigete 
nahas on inflammasoomid aktiveerunud nii epidermises kui ka dermises. Auto-
faagia on aktiveeritud vitiliigohaigete melanotsüütides ja keratinotsüütides. 
Leidsime, et vitiliigoga patsientide nahas on häirunud mitmete miRNAde aval-
dumine. Nendest miRNAdest miR-155 mõjutab melanogeneesi ja põletikulises 
vastuses osalevate geenide avaldumist nii melanotsüütides kui ka keratino-
tsüütides. 
 Selleks, et parandada teadmisi vitiliigo ja psoriaasi tekkemehhanismidest, 
parandada nende haiguste diagnoosimis- ja ravivõimalusi ning leida võimalikke 
prognostilisi markereid, on loomuliku immuunsuse ja miRNAde vallas vaja-
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